

AD\_\_\_\_\_

Award Number: W81XWH-09-2-0179

TITLE: Development of an Injectable Salmon Fibrinogen-Thrombin Matrix to Enhance Healing of Compound Fractures of Extremities

PRINCIPAL INVESTIGATOR: Stephen W. Rothwell

CONTRACTING ORGANIZATION: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.  
Rockville, MD 20852

REPORT DATE: September 2012

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved  
OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

<b>1. REPORT DATE</b> September 2012		<b>2. REPORT TYPE</b> Final		<b>3. DATES COVERED</b> 30 September 2009 – 31 August 2012	
<b>4. TITLE AND SUBTITLE</b>  Development of an Injectable Salmon Fibrinogen-Thrombin Matrix to Enhance Healing of Compound Fractures of Extremities		<b>5a. CONTRACT NUMBER</b>			
		<b>5b. GRANT NUMBER</b> W81XWH-09-2-0179			
		<b>5c. PROGRAM ELEMENT NUMBER</b>			
<b>6. AUTHOR(S)</b>  Stephen W. Rothwell  E-Mail: stephen.rothwell@usuhs.edu		<b>5d. PROJECT NUMBER</b>			
		<b>5e. TASK NUMBER</b>			
		<b>5f. WORK UNIT NUMBER</b>			
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Rockville, MD 20852		<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>			
		<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>			
		<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>			
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b>  Four treatments were compared in an acute femur fracture model in swine for their capacity to improve the progress of bone healing and regeneration. The treatments examined were 1) salmon fibrinogen and thrombin, 2) porcine fibrinogen and thrombin, 3) bovine collagen and a commercial FDA approved treatment called CopiOs. The treatments were instilled into the injury site and the bone was stabilized by surgical external fixation. The subject animals were maintained for 3 weeks and examined biweekly using fluoroscopy to visualize the bone healing and Near Infrared Spectroscopy, electric impedance measurement and Doppler ultrasound to assess the healing of the sound tissue. Wound severity was consistent in 29 animals. Cellularity and bone regeneration varied by treatment with CopiOS being the least effective in inducing a growth response and salmon fibrinogen and porcine fibrinogen being the most inductive. Computerized analysis of the CT and histology were consistent with human interpretation. A rat survival mode has been developed to permit longitudinal PET studies.					
<b>15. SUBJECT TERMS</b> Fracture, bone healing, osteogenesis, salmon thrombin, fibrinogen, porcine, rodent, PET, CT					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  UU	<b>18. NUMBER OF PAGES</b>  ÁÍ	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b> U	<b>b. ABSTRACT</b> U	<b>c. THIS PAGE</b> U			<b>19b. TELEPHONE NUMBER (include area code)</b>

## **Table of Contents**

	<u>Page</u>
<b>Introduction.....</b>	<b>4</b>
<b>Body.....</b>	<b>4</b>
<b>Key Research Accomplishments.....</b>	<b>8</b>
<b>Reportable Outcomes.....</b>	<b>8</b>
<b>Conclusion.....</b>	<b>9</b>
<b>References.....</b>	<b>10</b>
<b>Appendix .....</b>	<b>11</b>

## **Development of an Injectable Salmon Fibrinogen-Thrombin Matrix to Enhance Healing of Compound Fractures of Extremities**

### **INTRODUCTION**

Penetrating injuries to extremities caused by blast fragmentation include extensive tissue damage accompanied by uncontrolled bleeding and high grade open fractures (Holcomb, Stansbury et al. 2006; Holcomb, McMullin et al. 2007). Bleeding at distal sites is controlled by tourniquet application but proximal wounds (ex. femoral) may be inaccessible. Serious bone injuries can be later treated by autologous bone grafts but bone grafts are subject to the possibility of serious side effects, such as morbidity and infection at the secondary site, pain and limitations for the supply of bone graft material. To attempt to overcome these limitations, new directions in the first response to penetrating wounds are required. Bleeding must be controlled by the direct application of a hemostatic agent deep into the wound at the site of the bleeding. Second, fragmented bone must be stabilized if the limb will be saved (Brandoff, Silber et al. 2008). The approach of this project is to inject fibrin sealants directly into the wound to stop the bleeding and into the bone lesion to provide an environment that will sustain the cellular component of bone and encourage bone regeneration. The objective of this project is to develop a new injectable reagent that can form a matrix at the site of a bone fracture and enhance the preservation of bone tissue following injury. This treatment should permit successful surgical repair and accelerate subsequent healing. Specific parameters that will be examined will be 1) cell viability of bone fragments at the site of injury as well as those embedded in the injected matrix but removed from contact with the primary bone, 2) resistance of the injured bone to necrosis, 3) induction of new bone growth at the site of injury and 4) comparison of rate of bone regeneration in animals treated with different implantable matrix. The material to be tested in this project is a salmon fibrin matrix derived from salmon fibrinogen and thrombin (Wang, Gorlin et al. 2000; Michaud, Wang et al. 2002; Rothwell, Reid et al. 2005).

### **BODY**

The methodology of this project is to create a fracture in the femur of pigs that will replicate the injuries caused by high velocity penetrating projectiles. The fracture is then stabilized by external fixation according to standard practice and the treatment agent is injected into the wound site. The limb is then further stabilized by the application of a fiberglass cast. The animals receive Fentanyl patches the day before surgery to initiate analgesia and continue to wear the patches for 2 weeks following surgery. Buprenorphine and metacam (Meloxicam) are also administered at the time of surgery for short term pain relief. Fluoroscopy is performed before and after injury to ascertain the degree of injury and to assess the reproducibility of the injury. Blood is drawn to permit assays for immune reaction and infection. Physiological monitoring of the animal to measure vital signs, blood flow and edema in the hind legs is conducted to

track changes following injury. Monitoring is continued every three days to include bandage change, fluoroscopy and physiological parameters. At three weeks the animals are sacrificed and the femurs are recovered for analysis. The bones are imaged using X-ray computerized tomography. Following imaging, the specimens are fixed in formaldehyde and processed for histological examination. Expert analysis of the histological specimens is provided by MAJ Eric Lombardini, veterinary pathologist.

In vitro studies are conducted using mesenchymal stem cells in culture. The cells are cultured in media with and without the treatment agents and assessed for cell viability and induction of osteogenesis. The osteogenesis is measured by cell staining and examination for morphological changes in the cells and by RNA analysis. Using real time PCR, the RNA expression is analyzed to determine if the different treatments have up-regulated the expression of bone-specific genes.

Changes to the methodology for year 3:

1. Computerized analysis of the bone sections and the CT scans were conducted minimize human bias in the analysis of the samples. The histology bone slides were digitally scanned with an Olympus/Hammatsu Nanozoomer and images were collected with the NDP Nanoviewer software. Files were then analyzed using Visiopharm/ Vismorph software package (Medicon Valley, Denmark) to quantify bone, cartilage and fibrous tissue in the section.
2. CT scans and plain radiographs were examined visually and by software analysis. Co-investigators, blinded to treatments, analyzed the CT scans for bone alignment, inflammation, bone filling and calcification. Numerical scores from 1-5 were assigned for each parameter and mean scores for each group were calculated. Computer analysis of the CT scans was accomplished using VivoQuant (Invicro-Imaging Services, Boston MA).
3. Development of a rat femur injury that can be followed longitudinally by CT and PET scanning. Because of the size of the porcine femur, CT scanning could only be accomplished after euthanasia of the animal and isolation of the bone. This precludes longitudinal studies that follow healing over an extended period. To work around this limitation, we have developed a rat model of the femur injury. Animals are treated with fibrinogen/thrombin preparations (salmon and rat), Copios bone filler or no treatment. Animals are then assessed by CT and NaF<sup>18</sup> Positron Emission Tomography (PET). PET permits localization and quantitation of the uptake of the fluoride to the bone injury site.

Progress in the project

In the **first year** of this project we have made progress on both the cell culture aspects of the project and the animal studies. By establishing stem cell cultures that


have the capacity to differentiate into bone-producing cells, we have demonstrated that, with controlled culture conditions, we can manipulate the expression of bone-specific proteins. The expression of these proteins can be visualized by microscopic examination of the cells and by biochemical detection of bone-specific RNA. The expression levels can be modulated by culturing the cells with different matrices. We found that the salmon fibrinogen and thrombin matrix induced increases in 21 proteins associated with osteogenesis. Furthermore, these changes were dependent on the concentration of the salmon proteins in matrix. For the *in vivo* aspects of the project, we have established the basic femur fracture model and determined an efficient and humane method for caring for the animals post-operatively. We have currently treated nine animals with either salmon fibrinogen (3), porcine fibrinogen (3), unmodified collagen (2) and TR Matrix (1). The bones have been CT scanned and prepared for histological examination. One set of salmon fibrinogen-treated bone fracture slides have been prepared and examined. Blood samples have been collected and basic blood parameters measured and evaluated for the production of adverse immune reaction.

In the **second year**, 4 different treatments were tested. These treatments were 1) salmon fibrinogen and salmon thrombin, 2) porcine fibrinogen and porcine thrombin, 3) a commercially available, FDA approved bone matrix called CopiOS and 4) bovine collagen. Our plan was to have four groups of eight animals. To date we have collected data from 30 animals. Several animals have been excluded from the data group due to termination prior to the completion of the trial period. Data collected included biological samples for immunology testing, physiological parameters to assess wound healing, fluorography (X-rays) to assess the bone formation and growth and CT (computed tomography) for 3-D reconstruction of the bone. In addition, all bones were preserved for histological examination by Dr. Eric Lombardini, veterinary pathologist at AFRII. Our final results are still being analyzed because the last of the animals was only recently completed. However, preliminary results show that there are definite differences between animals, both at the level of radiographic examination and histological examination. The analysis of the radiographs is quantifying the degree of displacement of the bone, severity of injury and degree of fibrosis and calcification of the injury site. Sepsis at the bone fixation site and the injury site is also evaluated since this may have an impact on the healing process. Numerical scores are assigned to each parameter to permit comparison between samples and groups. The histological slides are assessed in a similar fashion with numerical score assigned to infection, bone formation and osteoclast frequency. It will not be possible to make conclusions on the virtues of one treatment group versus another until we have analyzed all of the histological data.

A final aspect of the project was a subproject concerning the effectiveness of the pain alleviation protocol that was used. Dr. Joseph Royal, veterinary fellow, has conducted this project in which he administered femoral and sciatic nerve blockades in addition to the fentanyl patches that were the standard of care for the animal. These data are currently being analyzed for heart rate variability and activity levels which have been used as criteria for pain in other studies.

In the **third year**, we completed the analysis of the swine data concerning the bone healing process, non-invasive measures of tissue damage and healing and the effectiveness of nerve blockades as a method of alleviating extremity pain in swine. Manuscripts have been prepared and submitted on these topics (manuscripts are attached). In addition, a CRADA has been implemented with Dr. Ki Chon of Worcester Polytechnic Institute, MA to collaborate on analysis of the ECG data and how it relates to subjective measurements of pain.

A new bone healing protocol has been developed in rats to permit the study of bone healing over time. In this protocol, an injury is produced in the mid-femur with a motorized drill, resulting in a uniform, regularly shaped lesion that can be reproducibly made. The animals are treated with fibrinogen/thrombin preparations made from rat or salmon protein preparations, the commercial bone filler CopiOS or recovered without any treatment. At 2 days, 7 days, 14 days and 28 days the animals are injected with radioactive fluoride and scanned for deposition of radioactivity in the injury site. The radioactivity can be visualized (Figure 1) and quantitated. Changes in radioactivity will be normalized to the uninjured femur and compared between treatments. CT and PET scans will be collected.



**Figure 1.** PET and CT scans from a control rat with a femur injury without treatment. Panels A and B show the PET and CT scans, respectively, at Day 2 following the injury. Panels C and D show the PET and CT scans of same animal at Day 7 following injury. The yellow arrow indicate the site of injury and the uptake of  $\text{NaF}^{18}$  following 30 minute incubation with the tracer. Rate of uptake is greater at Day 7 compared to Day 2.

## **KEY RESEARCH ACCOMPLISHMENTS**

- **Completed** the full analysis of the swine femur CT scans with computer analysis.
- **Completed** the full analysis of the swine femur histology slides with computer analysis.
- **Wrote and submitted** manuscript on the bone healing results.
- **Completed** initial analysis of cardiac tracings from twenty animals treated with regional nerve blocks.
- **Wrote and submitted** manuscript on the efficacy of nerve blockades in swine in comparison to conventional Fentanyl patch analgesia.
- **Completed** the full analysis of the swine impedance, Doppler flow and near Infrared measurements.
- **Wrote manuscript** on the use of surrogate measures of bone and tissue healing in preparation for submission
- **Developed** rat bone healing protocol with PET/CT scanning.
- **Wrote and submitted** application for in-house pilot grant for rat PET/CT imaging project.

### **Personnel receiving salary from this research project**

Dr. Michael Bodo, research physiologist

## **REPORTABLE OUTCOMES**

Presented the following posters on the therapeutic qualities of salmon fibrinogen and thrombin:

- Bodo M., S. W. Rothwell, T. Settle, J. Royal, E. Lombardini and E. Sawyer. 2012. Surrogate Markers of Healing from Penetrating Traumatic Compound Femur Fracture in Swine. USU Research Week, Bethesda, MD.
- Bodo M., S. W. Rothwell, T. Settle, J. Royal, E. Lombardini and E. Sawyer. 2012. Surrogate Markers of Healing from Penetrating Traumatic Compound Femur Fracture in Swine. USU Research Week, Bethesda, MD.
- Jiang, G., S.W. Rothwell, Jacobowitz, D., Mueller, G., Pollard, H. 2012. A rational approach for protein sequencing. USU Research Week, Bethesda, MD.
- Rothwell, S.W., Eric Lombardini, Michael Bodo, Evelyn Sawyer, Joseph Royal and Timothy Settle. 2012. Enhancing the Healing of Penetrating Traumatic Compound Femoral Fractures in Swine with Injectable Fibrinogen Preparations. USU Research Week, Bethesda, MD.
- Royal, J.M., T. L Settle, M. Bodo, E. Lombardini, M. L Kent, J. Upp, and S. W. Rothwell. 2012. Ultrasound-guided Regional Anesthesia in a Swine Femur Fracture Model. USU Research Week, Bethesda, MD.

Submitted the following manuscripts:

- Rothwell, S.W., E. Sawyer, E. Lombardini, J. Royal, H. Tang, M. Bodo, T. L. Settle 2012. Comparison of fibrinogen and collagen-based treatments for penetrating wounds with comminuted femur fractures in a swine model. *J Special Oper Med.*
- Royal, J.M., T. L Settle, M. Bodo, E. Lombardini, M. L. Kent, J. Upp, and S.W. Rothwell. 2012. A Comparison of Postoperative Analgesic Effects of Ultrasound-guided Regional Anesthesia in a Swine Femur Fracture Model. *J Am Assoc Lab Animal Sci.*

Prepared the following manuscript for submission:

- Bodo, M., T.L. Settle, J.M. Royal, E. Lombardini, E. Sawyer, S.W. Rothwell. 2012. Noninvasive monitoring of healing from penetrating traumatic compound femur fracture in swine. *J Clinical Monitoring and Computing*

Published manuscript:

- Floyd, C.T., S.W. Rothwell, R. Martin, J. Risdahl and N. Rose. 2012. A salmon thrombin-fibrinogen dressing allows greater survival and preserves distal blood flow compared to standard kaolin gauze in coagulopathic swine with lethal injury. *J Special Operations Medicine. J Special Operations Medicine.* 12(2): 16-26.

## CONCLUSIONS

In summary, we have made substantial progress in achieving the goals outlined in our initial project proposal. We have collected the data from all of our animals and have made complete analysis and conclusions. We completed the computerized analysis that has quantitated the area of bone calcification and validate the observational measurements of the Dr. Lombardini. We also completed a computerized analysis of the CT scans of the healing bone. We have also used the Infrared spectroscopy, Doppler and impedance measurements to demonstrate that these could useful, non-invasive measurements of healing.

Our conclusions are that fibrinogen-based treatments showed a trend towards better healing based on cellular and mineralization patterns than did the collagen or mineral-blood preparations. However, the limited numbers of animals in this trial did not allow these measurements to reach statistical significance in the measured parameters, even with the computerized methods.

To counter this problem, we have developed a rat injury model that will permit larger numbers of animals and multiple scanning sessions/animal over time. With the preliminary data acquired on the limited animals done on the small animal protocol, we have applied for a small pilot grant and will use the additional data from that study to apply for a grant that will be fully powered to achieve statistical significance.

## REFERENCES

- Brandoff, J. F., J. S. Silber, et al. (2008). "Contemporary alternatives to synthetic bone grafts for spine surgery." Am J Orthop **37**(8): 410-414.
- Holcomb, J. B., N. R. McMullin, et al. (2007). "Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004." Ann Surg **245**(6): 986-991.
- Holcomb, J. B., L. G. Stansbury, et al. (2006). "Understanding combat casualty care statistics." J Trauma **60**(2): 397-401.
- Michaud, S. E., L. Z. Wang, et al. (2002). "Purification of salmon thrombin and its potential as an alternative to mammalian thrombins in fibrin sealants." Thromb Res **107**(5): 245-254.
- Rothwell, S. W., T. J. Reid, et al. (2005). "A salmon thrombin-fibrin bandage controls arterial bleeding in a swine aortotomy model." J Trauma **59**(1): 143-149.
- Wang, L. Z., J. Gorlin, et al. (2000). "Purification of salmon clotting factors and their use as tissue sealants." Thromb Res **100**(6): 537-548.

## Appendix Three Attached manuscripts

### **Comparison of fibrinogen and collagen-based treatments for penetrating wounds with comminuted femur fractures in a swine model**

Stephen W. Rothwell<sup>1</sup>, Evelyn Sawyer<sup>2</sup>, Eric Lombardini<sup>3</sup>, Joseph Royal<sup>4</sup>, Haiying Tang<sup>5</sup>, Michael Bodo<sup>6</sup>  
Timothy L. Settle<sup>4</sup>

<sup>1</sup> Department of Anatomy, Physiology and Genetics, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814

<sup>2</sup> Sea run Holdings Freeport, ME<sup>3</sup> Department of Comparative Pathology, Armed Forces Radiobiology Research Institute, Bethesda, MD 20814

<sup>3</sup> Department of Comparative Pathology, Armed Forces Radiobiology Research Institute, Bethesda, MD 20814

<sup>4</sup> The Center for Laboratory Animal Medicine, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814

<sup>5</sup> Department of Radiology, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814

<sup>6</sup> Center for Neurobiology and Regenerative Medicine, The Uniformed Services University of the Health Sciences, Bethesda, MD 20814

**DISCLAIMER** The opinions or assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the US Army, Department of Defense or the Uniformed Services University of the Health Sciences.

### **Abstract**

**Introduction:** Military service members in combat operations often sustain injuries to the extremities from high speed projectiles resulting in bleeding and comminuted open fractures. Severe injury with bone fragmentation can result in limb amputation. Surgical treatment options include materials that promote osteogenesis and bone proliferation such as growth hormones, stem cells or mineralized matrix adjuncts. However, none of these are amenable to usage by the first responder and nor do they address the question of hemorrhage control which is often a common problem in traumatic injuries.

**Hypothesis:** Our hypothesis was that treatment with a fibrinogen-based protein mixture at the time of the bone injury will provide both hemostasis and a supportive environment for preservation of injured bone.

**Methods:** A comminuted femur fracture was produced in 28 female Yorkshire swine and one of four treatments was instilled into the wound immediately following injury. Each animal was evaluated for the following parameters: inflammation, new bone growth, osteoclast proliferation, callus formation and femur wound cavity fill, using post-mortem Computed Tomography and analysis of histological sections.

**Results:** Overall, salmon fibrinogen-thrombin and porcine fibrinogen-thrombin showed a trend for improved healing based on bone filling and calcification. However, statistically significant differences could not be established between treatment groups.

**Conclusions:** These findings indicate that a fibrinogen-thrombin matrix may be a useful as an immediate response product to enhance fracture healing. Salmon fibrinogen/thrombin has the advantages of cost and pathogen profile compared to mammalian fibrinogens.

## Introduction

Blast injuries have become increasingly more frequent and severe in recent military and civilian incidents as terrorists become more sophisticated in their application of bomb-making technology. An additional escalation of the number of casualties has been caused by the inclusion of metal fragments placed in the explosive charge, resulting in the widespread discharge of shrapnel. In a study published by Weil et al. [1] that examined terrorist bombings in Israel, penetrating injuries to the extremities caused by high explosive attacks were associated with extensive tissue damage that was usually accompanied by high grade open fractures.

For American military members, operational and logistical operations in Iraq and Afghanistan often rely on ground convoy movements that expose service members to risk of injury or death from roadside explosives. Vehicle-borne explosives have often been deployed against fixed sites. The force of the explosive devices, the accompanying shock wave (“wind of explosion”) and the storm of shrapnel and debris carried by the explosion can cause massive soft tissue and orthopedic injuries. Extensive deployment of Kevlar helmets and body armor has mitigated the incidence of penetrating head and body wounds, but extremity injuries with concomitant bone fragmentation have continued to be a source of concern [2, 3]. It is estimated that 60-70% of injuries now occur in the extremities[4]. A treatment is needed that can be directly inserted into the wound site to stop bleeding and stabilize the shattered fragments.

Penetrating injuries to extremities caused by blast fragmentation often involve extensive tissue damage accompanied by uncontrolled bleeding and high grade open fractures [5, 6]. Bleeding at distal sites may be controlled by tourniquet application but wounds in more proximal sites, such as the proximal femoral area, may be inaccessible to tourniquets. Serious bone injuries can be later treated by autologous bone grafts but bone grafts can have serious side effects, such as infection at the donor site and pain. Furthermore, the quantity of bone graft material that can be obtained by this method is limited. To attempt to overcome these limitations, new directions in the first response to penetrating wounds are required. First, bleeding must be controlled by the direct application of a hemostatic agent deep into the wound at the site of the bleeding. Second, fragmented bone must be stabilized if the limb will be saved [7]. Third, any intervention must be relatively inexpensive and environmentally stable enough to be backpack compatible.

The hypothesis of this project was that lyophilized fibrinogen/thrombin preparations rehydrated and instilled into the wound shortly after injury would control hemorrhage and stabilize bone fragments. The approach was to inject fibrin sealants directly into the wound and the bone lesion to provide an environment that will sustain the cellular component of bone and encourage bone regeneration. This technique can also provide a medium to support the growth of cells, either native or exogenous mesenchymal stem cells, that may be implanted into the site [8, 9]. This treatment should permit successful surgical repair and accelerate subsequent healing. The materials tested in this project were two fibrinogen preparations, swine and salmon fibrinogen, bovine collagen and commercial bone filler. A combination of salmon thrombin and fibrinogen [10-12] has been tested as a hemostatic agent in other projects and has been shown to be an effective hemostatic reagent with a commercially viable cost.

## Materials and Methods

### *Mesenchymal stem cell cultures*

Human mesenchymal stem cells were purchased from Celprogen, Inc. (San Pedro, CA) and grown either on coverslips in 6-well cell culture plates or directly in 6-well culture plates with or without surface modification. Media designated by the company as “maintenance” or “differentiation” media was used to either permit the cells to proliferate in the undifferentiated state or induce differentiation along the osteogenic pathway. Bovine collagen (Sigma-Aldrich, St Louis, MI) or salmon fibrinogen/thrombin (Sea Run Holdings, Eastport, ME) preparations were used to coat the surface of slides or wells to induce differentiation for microscopy and RT-PCR analysis. Concentrations of fibrinogen and thrombin tested were: 5 mg/mL fibrinogen 10u/mL thrombin, 5 mg/ml fibrinogen 100u/ml thrombin, 30 mg/ mL fibrinogen 10u/ mL thrombin, 30 mg/ mL fibrinogen 100u/ mL thrombin, 50 mg/ mL fibrinogen 10u/ mL thrombin and 50 mg /mL fibrinogen 100u/ mL thrombin. For comparison, Greiner Bio-one collagen (Type1) coated plates (Greiner Bio-One North America, Inc., Monroe, NC) were used with complete or differentiation media.

Differentiation was assessed morphologically by the ability to deposit calcium phosphate and metabolically by the up-regulation of osteogenic RNA. Morphological assessment was performed using two different staining techniques to identify the mineral deposition, 1) Von Kossa staining which detects the presence of phosphate ions and 2) Alizarin Red which detects calcium deposits.

### *RT-PCR*

Mesenchymal cells were harvested from 6-well culture plates digested with trypsin and collected by centrifugation at 300xg for 5 min. RNA was prepared using the Qiagen RNeasy spin column procedure (Qiagen, Valencia, CA) and evaluated for quality by electrophoresis. RT-PCR was performed using SABiosciences Human Osteogenic pathway kit and reagents (Frederick, MD). Briefly, genomic DNA was removed using the SABiosciences Genomic DNA elimination kit, the reverse transcriptase reagents were added to the genomic elimination sample and incubated at 42C for 15 min before stopping the reaction by incubation at 95C. The completed First Strand cDNA solution was mixed with SABiosciences RT<sup>2</sup> qPCR Master Mix and pipetted onto the 96 well pathway plate. The plates were developed on a Roche LightCycler 480 PCR cycler (Roche Applied Science, Indianapolis, IN) and the results analyzed using the Roche Light cycler software package.

## Surgical preparation of animals

### Animal care standards

All animal procedures were conducted according to a Uniformed Services University Institutional Animal Care and Use Committee approved protocol. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adhered to principles stated in the *Guide for the Care and Use of Laboratory Animals*, [NRC Publication, 2011 edition].

### Animal surgical model

Female Yorkshire swine (*Sus scrofa Domestica*) (weighing 35-40kg) were prepared for surgery and monitored during the procedure as described previously [11]. A transdermal fentanyl patch (50 ug/hr; Watson Laboratories, Inc., Corona, CA) was placed on each animal 18 hours prior to surgery to provide postoperative analgesia. Anesthetic induction was accomplished by intramuscular injection of tiletamine-zolazepam (Telazol<sup>©</sup>) (4.4mg/kg) (Fort Dodge Animal Health, Fort Dodge, Iowa). The animals were then intubated and anesthesia maintained using isoflurane (2-3%). The injury was produced at the right femoral midshaft using a Schermer KS self-retracting penetrating captive bolt gun (QC Supply, Schuyler, NE). This resulted in tissue and muscle damage at the point of entry and full penetration of the femoral bone, producing a non-compressible bleeding wound and a compound fracture following the method of Majetschak et al. [13, 14]. A biplanar type I fixation device with threaded half pins was placed proximal and distal to the fracture in a bilateral configuration with interconnecting bars as previously described in general veterinary surgery texts [15]. A non-adherent dressing (Telfa ,Tyco Healthcare, Mansfield, MA) was applied to the wound and the entire leg was immobilized and encased in a cast (Vetcast Plus, 3M Health Care, Neuss, Germany). This dressing/cast was secured to the pig using Elastikon elastic tape (Johnson & Johnson Consumer Products, Skilman, NJ). Analgesics (0.3 mg, buprenorphine; Hospira, Inc., Lake Forest, IL) were administered as needed for pain control and sedation during the first 3 days post-surgery. The animals were sedated twice a week to permit cleansing of the pin sites and blood collection. At days 7, 14 and 21 radiographs were taken to assess union at the fracture. Bioimpedance measurement and Doppler ultrasound was used to estimate blood flow, tissue oxygenation and edema formation (Bodo, manuscript in preparation). At day 21, animals were euthanized by IV injection of pentobarbital and the femur was dissected for computed tomography (CT) and collection of tissues for histology.

### Bone injury treatments

Four different preparations were tested for their effects on bone formation: (1) salmon fibrinogen and thrombin (Sea Run Holdings, Inc., Eastport, ME, (2) porcine fibrinogen and thrombin (Enzyme Research, Inc. South Bend, IN), (3) bovine collagen (Sigma-Aldrich, St. Louis, MO) and (4) CopiOS<sup>®</sup> Bone Void Filler (Distributed by Zimmer, Inc., Warsaw, IN; manufactured by Kensey Nash Corp, Exton, PA)(BF) . Eight animals were assigned to each treatment group. Salmon fibrinogen (20 mg/mL) and thrombin (450 U) (SFT) and porcine fibrinogen (18.8 mg/mL) and thrombin ( 287.2 U) (PFT) solutions were filter sterilized separately and the fibrinogen and thrombin

were combined during instillation into the wound. Prior to use, CopiOS<sup>R</sup> was mixed with 5 mL citrated autologous blood. Bovine collagen was sterilized by irradiation (5kGy; JL Shepherd Mark 109 Cobalt source, San Fernando, CA), suspended in 5 mL sterile PBS, and instilled into the wound. Placement of a treatment into the wound site was made possible by a 3 mL syringe with the tip cut off to produce an open-ended tube, which was then inserted into the injury track down to the level of bone lesion. The treatment material was deposited into the syringe barrel and the syringe plunger was inserted to expel the treatment material as the syringe barrel was withdrawn. Two inert plastic radiopaque beads (1mm diameter) were included with the treatment in five animals to verify correct placement of the treatment material into the fracture site. Plain radiographs were obtained with an Insight Fluorscan C-arm fluoroscopy machine (Hologic, Inc. Bedford, MA). CT scans were performed on a Siemens Inveon Multimodal system (Siemens USA, Malvern PA).

#### *Analysis of bone slides and CT scans*

Following euthanasia, each femur was isolated and used for CT imaging. The femoral head and the lateral condyle were then detached to permit infiltration of paraformaldehyde, and the tissues were decalcified, sectioned, and stained with hematoxylin and eosin. Images were analyzed in a blinded fashion by a veterinary pathologist (EL) and coded according to morphology, inflammation, new bone growth, presence of cartilaginous islands and the absence or presence of osteoclasts. The slides were digitally scanned with an Olympus/Hammatsu Nanozoomer and images were collected with the NDP Nanoviewer software. Files were then analyzed using Visiopharm/ Visiomorph software package (Medicon Valley, Denmark) to quantify bone, cartilage and fibrous tissue in the section.

CT scans and plain radiographs were examined visually. Co-investigators (SR and TS), blinded to treatments, analyzed the CT scans for bone alignment, inflammation, bone filling and calcification. Numerical scores from 1-5 were assigned for each parameter and mean scores for each group were calculated. Computer analysis of the CT scans was accomplished using VivoQuant (Invicro-Imaging Services, Boston MA).

#### *Data analysis*

Simple summary statistics and graphical displays were used to describe the results of this study. Summary statistics included means, standard deviations, and confidence intervals. Analysis of variance was conducted for multiple group comparison. Graphical displays included bar and box plots.

## **Results**

#### *Human mesenchymal cells grown on a salmon fibrin matrix are induced to express osteogenic proteins*

Human bone marrow-derived mesenchymal stem cells obtained from Celprogen, Inc. can be maintained as undifferentiated stem cells or induced to attain differentiated morphology based on the media and surface treatment of the culture flasks. To determine if a salmon fibrinogen/thrombin matrix could induce a similar transformation, cells were cultured for one week in maintenance flasks, flasks coated with collagen type I or coated with protein matrices formed by the clotting of salmon fibrinogen with salmon thrombin. The cellular response to the different conditions was assessed histologically. As shown in **Figure 1**, cells grown in the Celprogen maintenance media on

maintenance cell culture plates retained a non-differentiated morphology and stained negatively in the Von Kossa assay (**Figure 1**, panel A). When cultured in differentiation media which had the required growth factors for osteogenic differentiation, the cells changed their appearance and deposited calcium phosphate as indicated by the dark precipitates (**Figure 1**, panel B) resulting from alkaline phosphatase as detected by the Von Kossa assay. Cells grown on bovine collagen lost their contact inhibition and became confluent but did not show significant mineral deposits (**Figure 1**, panel C). In contrast, cells grown on a salmon fibrin matrix (50mg/mL fibrinogen with 10 units salmon thrombin) displayed rounded osteoblastic morphology with darkened Golgi regions and intense extracellular mineral deposits (**Figure 1**, panel D). This would indicate that components of the salmon fibrinogen/thrombin matrix have the capacity to alter the normal status of the cells.

RNA expression was quantitated using reverse transcriptase polymerase chain reaction RT-PCR and the osteogenic panel from SA Biosciences. Assays were run on undifferentiated cells to establish a baseline of RNA expression and cells grown on maintenance plates in differentiation buffer or fibrinogen coated plates for seven days. Even at this early time point changes could be detected (**Table1**). When cells were grown on coated plates for 21 days, more robust changes in the RNA profile could be observed. Cells were grown in (1) undifferentiating media on salmon fibrinogen (5 mg/mL) /thrombin (10 U) for 21 days, (2) undifferentiating media on salmon fibrinogen (50 mg/mL) /thrombin (100 U) for 21 days and (3) collagen coated plates in differentiating media for 21 days. As shown in **Table 2**, the cells grown on salmon matrices showed increases in 22 of the 86 proteins on the array when compared to the baseline values of the undifferentiated cells. This compares favorably with the cells grown in differentiating media on a collagen substrate. The proteins that are up-regulated fall into several major groups. One group is comprised of structural proteins such as the collagens and several different types of collagens were up-regulated. Type I is a collagen variety expected to be increased since it is found in bone, but type IV and type XI were also increased. Type IV is found in the basal lamina of epithelial cells while type XI is secreted by chondrocytes. This may reflect the natural progression of bone healing which often proceeds through a cartilage stage on its way to transforming into bone [11, 12]. Transcription factors comprise another group of proteins that play an important regulatory role in the expression of proteins and the subsequent phenotype that results from their expression. In this experiment, two SMAD proteins which interact with transforming growth factor and mediate the TGF- $\beta$  protein expression response were increased by the differentiation process. An interesting protein that was increased was the protein tuftelin which has been identified as a nucleating protein for tooth enamel. Teeth and bones are related structures but have distinct components and cellular components

#### *Surgical results- animal responses and results of surgical care*

The injury created by the bolt penetrator was a realistic reprisal of the type of injuries caused by penetrating projectiles. A path approximately 1 cm by 6 cm was created that passed through the skin, muscle and bone. The bone was reproducibly perforated by the bolt (**Figure 2A**). In addition, there was a variable element introduced by the unpredictable degree of fracturing surrounding the hole produced by the bolt. Sometimes, fragments of bone would be displaced from the shaft. Frequently, fracture lines would spiral out from the impact point. Fracture displacement was not always readily visible at the initial surgery and external fixation, but became evident several

days later as the bone would separate along the fracture lines (**Figure 2B**). Instillation of the treatment matrix filled the injury tract and, in the case of salmon and porcine fibrin treatments, effectively stopped any bleeding. Severe bleeding was not produced in this model because the femoral artery and vein were avoided, but there was slow bleeding from soft tissue that was quickly stopped by fibrinogen treatment (**Figure 3A**). This slow bleeding continued for some time after application of the collagen and CopIOS preparations, but volume of blood loss was minimal (less than 20 mL). Healing occurred uneventfully at the injury site (**Figure 3B**). Injuries treated with salmon fibrinogen routinely re-epithelialized with hair growth reoccurring (**Figure 3C**).

*Bone healing measured by radiography showed fibrous deposition and some calcification in all treatments*

Radiography was conducted weekly to monitor the healing progress in each animal. It can be appreciated from the radiographs that the animal movement caused a displacement of the bone fragments despite the insertion of four pins (two proximal and two distal) and stabilization with a box arrangement of four bars and fiber cast (**Figure 4**). With plane radiography, we could follow the deposition of a fibrous callous and the beginning of the calcification process. **Figure 5** shows the progression of healing of the femur. Panel A is a view of the uninjured bone and Panel B shows the bone immediately following injury. The arrow indicates the point of impact of the penetrating bolt. Panel C shows femur at 10 day post-injury. Note that the animal has put weight on the limb and, despite the fixation, has caused detraction of the bone. Fractures in the bone have widened and are indicated by the arrows. In Panels D and E (Days 16 and 21) the lesions in the bone are healing (arrow 1). Panels F and G are views from the post-mortem CT scan. Arrow 3 indicates filling of the lesion in the cortex. In contrast, the lesion site in the medulla, shown in the slice view in panel F, is still low density and is not equivalent to the uninjured regions of the marrow space. An unanticipated consequent of the placement of external fixation pins was the onset of infection at the pin sites. Although the sites were cleaned twice weekly, this was not sufficient to keep the sites infection free. In some cases, the infection migrated down the pins and by three weeks eroded the stability of the pins.

*Computed tomography of the isolated femurs permits qualitative and quantitative analysis of bone healing*

At the three week time point, the animals were euthanized and the hind legs were removed for analysis. The uninjured leg was used as a control limb for comparison to the injured bone. Following computer reconstruction, the images were presented as three-dimensional images and as planar sectional images (**Figure 5**). These images were analyzed independently by two investigators (SR, TL) for bone alignment, inflammation, bone filling and calcification (callus score) without prior knowledge of the treatment group. Callus and bone filling scores are shown in **Figure 6**. The pig (PFT) and the salmon (SFT) fibrinogen/thrombin treatments were slightly better in the callus score and the PFT was slightly better than the other treatment groups in the bone filling category. However, none of the treatments were substantially different to reach statistical significance in the numbers of animals observed (n=7 or 8/group).

Analysis of the CT scans by the Vivoquant software package permits quantitation of the bone density within the healing region. Bone density was hypothesized to equate to calcification and regeneration of bone. 3-

dimensional regions of interests were mapped out that included only the damaged and healing region and did not include the original bony cortex which would skew the density analysis. Using this measurement, bone densities were calculated. (**Figure 7**). Box plots show the range of mean density (measured in arbitrary voxel units) for each animal in the treatment groups. The mean density was similar but the range of density varied widely. The SFI and PFT – treated animals usually had the highest density healing but both groups also had one animal with lower than average density repair which increased the range of values.

#### *Histological analysis of the injured sites identifies different tissue responses to the treatments*

Slides for each animal were prepared from the fixed and decalcified femurs and transformed into digital files with Hammasutu Nanozoomer scanner. As was performed in the analysis for the CT scans, the histology slides were assessed by both expert human judgment and by computer-assisted analysis. Histopathologic diagnosis was conducted by a trained veterinary pathologist (EL) blinded to the treatments and scored based on inflammation scale 1-5 (minimal, mild, moderate, marked, severe); maturation (based on fibroblast infiltration, collagen deposition and myelofibrosis with 1=most immature to 5=most mature) and the presence of new bone growth (scored qualitatively on a 1-5 scale) **Figure 8**. The results are variable, but the scores between the new bone growth (**Figure 8A**) and inflammation (**Figure 8C**) show the same patterns. In both categories, the SFT had the highest scores, PFT and CopiOS bone filler (BF) were intermediate and the collagen was lowest.

The computer analysis of the slides was set up to distinguish three tissue types (bone, cartilage and fibrous tissue) and open space on the slides. **Figure 9** shows the scores for the percentage of each region of interest that was coded as either cartilage or bone. SFT appeared slightly higher for the presence of bone and BF was lowest, but as before, but none of the values achieved statistical significance. All of the cartilage values were very similar.

## Discussion

In this study, we compared the ability of four different treatments to stabilize a fragmented femur replicating the type of injury often encountered in traumatic accidents and military operations. These injuries present major difficulties in initial treatment and stabilization of the site and long-term survival of the limb. It is our goal to develop a field stable, transportable, easy-to-use bone stabilizer that can be applied following injury by the first responder.

Many factors may contribute to non-union of fractures, including nutritional or hormonal status, age of the patient, and presence of bacterial contamination. Atrophic non-unions may be due to inadequate blood supply or failure of callus formation at the fracture site. More severe instances of non-union may arise when pieces of the bone are totally missing. Mechanical stability at the fracture site must be achieved and failure to attain this may be a leading reason for non-union. In addition, while non-union is estimated to occur in approximately 2.5% of all tibia fracture repairs [16, 17], if vascular injury is involved, the frequency increases 5-6 fold [18, 19]. The phenomenon of non-union of fracture has led to the development of substances that can bridge the gap where the bone is absent. These substances typically seek to cause the migration of bone producing cells into the lesion or cause the differentiation and proliferation of osteogenic cells from precursors and stem cell populations [20].

The most commonly used substance for bone grafting is bone itself [21], preferably an autologous graft from the iliac crest of the patient. This material is still considered the "gold standard" of bone grafting [22, 23]. It is osteogenic (can induce new bone formation), osteoconductive (provides a surface for bone formation), and osteoinductive (can stimulate the differentiation of bone precursor cells). It is the only graft material that has been tested that fulfills all three of these criteria. Trabecular bone is preferred over cortical bone because of the larger numbers of cells contained within the trabecular bone. While the bone graft itself does not confer mechanical stability, if the fracture is stabilized by the surgical procedure, high rates of repair are common [24]. In contrast, bone marrow aspirate from the bone contains osteoprogenitor cells but is not osteoconductive and the numbers of stem cells, especially in elderly patients, may be low.

Because autologous bone grafting is not always feasible, other alternatives have been put forth. Allograft bone, stripped of organic material, will serve as a framework for vascularization and bone formation. In a similar fashion, mineralized beads composed of calcium sulfate, calcium phosphate or hydroxyapatite have been used. These materials can be effective in aiding bone union form by working as volume expanders. However, they only can work by osteoconduction, not by osteogenesis or osteoinduction [25] so better artificial alternatives are required.

The recognition that true bone regeneration relies upon (1) having the proper progenitor cells at the injury site, (2) the molecular signals that can drive these cells down the proper differentiation pathways, (3) the adequate vascular systems to nourish the developing bone and (4) a sturdy system of mechanical support, has led members of the tissue engineering field to propose alternative artificial systems that incorporate as many facets of the natural system as possible. The starting point for most of the systems is the fabrication of a matrix that will provide support and mechanical stability. The matrix may be inert and act solely as a carrier for cells and bioactive molecules or it may have osteoinductive properties of its own. Collagen has been a logical starting point for many of the engineered matrices since this family of proteins forms the natural ground substance of bone [26-29]. Collagen has been used in combination with hydroxyapatite crystals in various forms in a number of studies to support the growth of human bone marrow stromal cells [30, 31]. A second protein matrix that has been evaluated in different systems is the fibrin gel. Fibrin is a major component in blood clotting and plays a major role in wound healing. It has been proposed to have an intrinsic osteogenic influence of its own [32], but there is no clear consensus on whether or not fibrin matrices by themselves can promote bone growth. A report from Meyers et al. using mammalian fibrin reported osteogenic effects in bone fractures in dogs over 20 years ago [32]. Fibrin-based gels have been used in conjunction with hydroxyapatite-coated beads or mesenchymal stem cells, and were shown support bone regeneration [33-35]. Fibrin may also prevent resorption of bone grafts, making grafts more efficient [36]. Fibrin has also been used in conjunction with collagen pads with fibrinogen injected as a platelet-rich plasma solution into the graft site and was found to increase the formation of bone [27]. Preliminary work with salmon fibrin/thrombin matrices suggests that the fish protein is unique when compared to human or bovine fibrin in supporting cell growth. Cell culture studies growing primary neurons demonstrated that the cells grew better and extended longer axonal processes on the salmon protein substrate [37]. However, not all studies of the effect of fibrin on bone regeneration have been favorable. Zarate-Kalfopoulos et al, in a surgical repair model of a rabbit lumbar injury, reported a negative effect of autologous fibrin on bone fusion [38].

The four treatments tested in this study encompassed the major structural approaches to bone stabilization with two treatments based on fibrinogen, one treatment using collagen and the final treatment based on a combination of collagen and calcium phosphate that was mixed with the patient's own blood. The injury used in this study was produced by a penetrating bolt that caused soft tissue injury and penetrated completely through the bone, causing extensive fragmentation of the bone shaft. The healing injury was assessed for stability of the fracture site, the amount of filling of the bone void, degree of calcification and the level of inflammation.

Analysis of the results makes it clear that given the variability of the injury and the differences in the individual animal's course of recovery, a study of this sort will require larger numbers of animals and a longer course of development to generate data with statistical significance. The samples were examined by two very different methodologies; x-ray/CT scanning and histology. The first technology examines hard tissue and the latter examines the cellular components of the limb. So, using these two approaches, it is possible to appreciate the different aspects of healing. The data was also analyzed in two different ways. The first was a calculation of density values measured by the software interpretation of X-ray or histology data. Although this method still requires an investigator to select the region of interest, the program calculates different densities of bone formation. The second analysis relied on human interpretation of healing. Although it may be considered to be more subjective, this analysis was based on years of collective expertise of three experienced investigators.

From these various analyses, several trends emerged. The fibrinogen treatments (SFT, PFT) displayed a tendency for improved development in terms of new growth, callous formation and bone filling. The unmodified collagen (BC) group seemed to rank consistently lower and the bone filler (BF) treatment was usually intermediate. These numbers suggest that a larger sample size could produce results with significant results.

Soft tissue and skin regeneration were also assessed. From a hemostatic perspective, both of the fibrinogen preparations proved effective at stopping the bleeding that resulted from the injury. Although this was not a hemorrhage model and there was not a large amount of bleeding, 3 mL fibrinogen/thrombin solution injected into the wound site instantly sealed the wound. This was not the case with either of the other two treatments. Subsequent healing of the tissue proceeded similarly in the four treatments as judged from a gross anatomical sense. In comparison, histological analysis showed that the fibrinogen treatments seemed to be more active from an inflammatory perspective, with a higher score for the presence of neutrophils, reactive fibroblasts, lymphohistiocytes and active osteoclasts. The presence of the inflammatory response could have a contradictory influence on the bone healing process, although it is thought that the initial immune response has a positive effect in triggering osteogenic activity [39]. Treatment of mice with fractures with the anti-inflammatory drug, indomethacin, has been found to inhibit fracture repair [40]. However, when inflammation progresses into the chronic stages, as observed with rheumatoid arthritis, diabetes mellitus and sepsis, fracture healing time and complications such as non-unions can increase [39]. At three weeks of time post injury, the immune response may still be a positive stimulus for tissue repair.

Our hypothesis that the salmon fibrinogen would have a particular advantage in this setting was not conclusively proven as the pig fibrinogen also seemed to give good response in our bone healing model. This study does suggest that a fibrinogen based agent could form the basis for a practical application for the treatment of

penetrating injuries with major fractures. Our future studies will be focused on longitudinal studies in rats. This will permit us to follow the progression of the healing process through time at multiple times points by CT and PET scanning. Although this model may not mimic human anatomy and physiology as closely as the swine model presented in this paper, we expect that the scientific payoff of increased sample size and improved resolution of the biology of healing will more than compensate for this trade-off.

### Acknowledgements

The authors acknowledge the members of the USU Laboratory Animal Center for expert surgical and animal support and members of the Pathology Department, Armed Forces Radiobiology Research Institute for sample processing. B. Jones and K. Brady also provided expert technical assistant. The “first-last-author-emphasis” (FLAE) was used a basis for the sequence of contributors.

### References

1. Weil, Y.A., et al., *Long bone fractures caused by penetrating injuries in terrorists attacks*. J Trauma, 2007. **62**(4): p. 909-12.
2. Hofmeister, E.P., M. Mazurek, and J. Ingari, *Injuries sustained to the upper extremity due to modern warfare and the evolution of care*. J Hand Surg [Am], 2007. **32**(8): p. 1141-7.
3. Mabry, R.L., et al., *United States Army Rangers in Somalia: an analysis of combat casualties on an urban battlefield*. J Trauma, 2000. **49**(3): p. 515-28; discussion 528-9.
4. Covey, D.C., *Combat orthopaedics: a view from the trenches*,. J Am Acad Orthop Surg, 2006. **14** ((10 Suppl)): p. S10–S17.
5. Holcomb, J.B., et al., *Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004*. Ann Surg, 2007. **245**(6): p. 986-91.
6. Holcomb, J.B., et al., *Understanding combat casualty care statistics*. J Trauma, 2006. **60**(2): p. 397-401.
7. Brandoff, J.F., J.S. Silber, and A.R. Vaccaro, *Contemporary alternatives to synthetic bone grafts for spine surgery*. Am J Orthop, 2008. **37**(8): p. 410-4.
8. Ouyang, H.W., et al., *Mesenchymal stem cell sheets revitalize nonviable dense grafts: implications for repair of large-bone and tendon defects*. Transplantation, 2006. **82**(2): p. 170-4.
9. Rabie, A.B. and M. Lu, *Basic fibroblast growth factor up-regulates the expression of vascular endothelial growth factor during healing of allogeneic bone graft*. Arch Oral Biol, 2004. **49**(12): p. 1025-33.
10. Michaud, S.E., et al., *Purification of salmon thrombin and its potential as an alternative to mammalian thrombins in fibrin sealants*. Thromb Res, 2002. **107**(5): p. 245-54.
11. Rothwell, S.W., et al., *A salmon thrombin-fibrin bandage controls arterial bleeding in a swine aortotomy model*. J Trauma, 2005. **59**(1): p. 143-9.
12. Wang, L.Z., et al., *Purification of salmon clotting factors and their use as tissue sealants*. Thromb Res, 2000. **100**(6): p. 537-48.
13. Dudkiewicz, M., T.A. Harpaul, and K.G. Proctor, *Hemoglobin-based oxygen carrying compound-201 as salvage therapy for severe neuro- and polytrauma (Injury Severity Score = 27-41)*. Crit Care Med, 2008. **36**(10): p. 2838-48.
14. Majetschak, M., et al., *Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma*. J Trauma, 2004. **56**(5): p. 991-9; discussion 999-1000.
15. Wade Brinker, D.P., Gretchen Flo, *Handbook of Small Animal Orthopedics and Fracture Treatment* 1983, Philadelphia: W.B. Saunders Co.
16. Phieffer, L.S. and J.A. Goulet, *Delayed unions of the tibia*. J Bone Joint Surg Am, 2006. **88**(1): p. 206-16.
17. Brighton, C., et al., *Tibial non-union treated with direct currec=nt, capacitive coupling or bone graft*. Clin Orthop, 1995. **321**: p. 223-234.
18. Ring, D., J.B. Jupiter, and L. Gulotta, *Atrophic nonunions of the proximal ulna*. Clin Orthop Relat Res, 2003(409): p. 268-74.

19. Velazco, A., T.E. Whitesides, Jr., and L.L. Fleming, *Open fractures of the tibia treated with the Lottes nail.* J Bone Joint Surg Am, 1983. **65**(7): p. 879-85.
20. Patterson, T.E., et al., *Cellular strategies for enhancement of fracture repair.* J Bone Joint Surg Am, 2008. **90 Suppl 1:** p. 111-9.
21. Megas, P., *Classification of non-union.* Injury, 2005. **36 Suppl 4:** p. S30-7.
22. Sen MK, M.T., *Autologous iliac crest bone graft: Should it still be the gold standard for treating nonunions?* Injury, 2007. **38:** p. S75-S80.
23. Bauer, T. and G. Muschler, *Bone graft materials. An overview of the basic science.* Clin Orthops, 2000. **371:** p. 10-27.
24. Finkemeier, C.G. and M.W. Chapman, *Treatment of femoral diaphyseal nonunions.* Clin Orthop Relat Res, 2002(398): p. 223-34.
25. McKee, M.D., *Management of segmental bony defects: the role of osteoconductive orthobiologics.* J Am Acad Orthop Surg, 2006. **14**(10 Suppl): p. S163-7.
26. Bernhardt, A., et al., *Mineralised collagen--an artificial, extracellular bone matrix--improves osteogenic differentiation of bone marrow stromal cells.* J Mater Sci Mater Med, 2008. **19**(1): p. 269-75.
27. Chang, S.H., et al., *Fabrication of pre-determined shape of bone segment with collagen-hydroxyapatite scaffold and autogenous platelet-rich plasma.* J Mater Sci Mater Med, 2008.
28. de Mendonca Costa, A., et al., *Reconstruction of large cranial defects in nonimmunosuppressed experimental design with human dental pulp stem cells.* J Craniofac Surg, 2008. **19**(1): p. 204-10.
29. Kim, M., et al., *Effect of bone mineral with or without collagen membrane in ridge dehiscence defects following premolar extraction.* In Vivo, 2008. **22**(2): p. 231-6.
30. Kilic, A.R., E. Efeoglu, and S. Yilmaz, *Guided tissue regeneration in conjunction with hydroxyapatite-collagen grafts for intrabony defects. A clinical and radiological evaluation.* J Clin Periodontol, 1997. **24**(6): p. 372-83.
31. Dawson, J.I., et al., *Development of specific collagen scaffolds to support the osteogenic and chondrogenic differentiation of human bone marrow stromal cells.* Biomaterials, 2008. **29**(21): p. 3105-16.
32. Meyers, M.H. and M. Herron, *A fibrin adhesive seal for the repair of osteochondral fracture fragments.* Clin Orthop Relat Res, 1984(182): p. 258-63.
33. Kim, S.S. and B.S. Kim, *Comparison of osteogenic potential between apatite-coated poly(lactide-co-glycolide)/hydroxyapatite particulates and Bio-Oss.* Dent Mater J, 2008. **27**(3): p. 368-75.
34. Yang, P., et al., *Prefabrication of Vascularized Porous Three-Dimensional Scaffold Induced from rhVEGF(165): A Preliminary Study in Rats.* Cells Tissues Organs, 2008.
35. Trubiani, O., et al., *Regenerative potential of human periodontal ligament derived stem cells on three-dimensional biomaterials: A morphological report.* J Biomed Mater Res A, 2008.
36. Segura-Castillo, J.L., et al., *Reduction of bone resorption by the application of fibrin glue in the reconstruction of the alveolar cleft.* J Craniofac Surg, 2005. **16**(1): p. 105-12.
37. Ju, Y.E., et al., *Enhanced neurite growth from mammalian neurons in three-dimensional salmon fibrin gels.* Biomaterials, 2007. **28**(12): p. 2097-108.
38. Zarate-Kalfopoulos, B., et al., *[Use of fibrin glue in combination with autologous bone graft as bone enhancer in posterolateral spinal fusion. An experimental study in New Zealand rabbits].* Cir Cir, 2007. **75**(3): p. 201-5.
39. Claes, L., S. Recknagel, and A. Ignatius, *Fracture healing under healthy and inflammatory conditions.* Nat Rev Rheumatol, 2012. **8**(3): p. 133-43.
40. Lu, C., et al., *Anti-inflammatory treatment increases angiogenesis during early fracture healing.* Arch Orthop Trauma Surg, 2012.

**Figure legends**

**Figure 1** Differentiation of human mesenchymal stem cells on salmon fibrinogen matrices. Cells were grown in Celprogen maintenance media on maintenance plates (A), in Celprogen differentiation media (B), on collagen matrix (C) or on a salmon fibrinogen matrix, 50mg/mL fibrinogen with 10 units salmon thrombin (D). Cells were stained with the Von Kossa stain to detect calcium phosphate precipitates deposited caused by the induction of alkaline phosphatase activity. Inset in Panel D indicates the cytoplasmic mineral deposits. Bar, 100um.

**Figure 2.** Perforating bone injury was produced in the midshaft of the femur. Panel A shows the isolated bone removed immediately after injury without treatment or surgical fixation. Panel B a plane X-ray of the injured bone in situ.

**Figure 3.** Progression of wound healing at the wound site. Panel A shows the wound at time of time of injury. Application of salmon fibrin treatment results in an instantaneous clot. Panel B shows scab formation as the wound site healed (7 days). By 21 days, the wound site had typically re-epithelialized with hair regrowth (Panel C). Arrows show ink mark used for orientation during surgery. The ink marks can be used for comparison of the wound status at the different times during healing. Bar, 1 cm.

**Figure 4.** Stabilization of femur injury by external fixation. The anatomy of the swine is not conducive to good stabilization of a fractured femur solely by a cast. Therefore, the bone was stabilized by placement of four surgical pins and fixed by an external apparatus. The frame was protected with a fiberglass cast and the entire dressing was secured with Elasticon tape (Johnson and Johnson, Inc.).

**Figure 5.** Progression of healing of the femur. Panel A, uninjured bone and Panel B, bone directly following injury. The arrow indicates the point of impact of the penetrator bolt. Panel C shows femur at the 10 day point. There has been movement in the bone. Cracks in the bone have widened and are indicated by the arrows. In Panels D and E (Days 16 and 21) the lesions in the bone are healing (arrow 1). Panels F and G are views from the post-mortem CT scan. Arrow 3 indicates the lesion in the cortex which is filling in. In contrast, the lesion site in the medulla (arrow 2), shown in the slice view in panel F, is still low density and is not equivalent to the uninjured regions of the marrow space.

**Figure 6.** Relative callus and bone filling scores as assessed by investigator CT analysis. Examination of the CT scan for each animal was examined by the investigators separately and then in consultation to reach a consensus score for callus formation and bone filling. Scores from 1-5 were assigned based on wound filling, bridging of the break and calcification. SFT = Salmon fibrinogen/thrombin, PFT = porcine fibrinogen/thrombin, BC = Bovine collagen and BF = CopiOS bone filler.

**Figure 7.** Analysis of bone density by VivoQuant Imaging software. The range (box plot), mean (dark line) and median (light line) of the repaired bone was calculated using vivoQuant analysis. SFT = Salmon fibrinogen/thrombin, PFT = porcine fibrinogen/thrombin, BC = Bovine collagen and BF = CopiOS bone filler.

**Figure 8.** Analysis of histology slides by a board-certified veterinary pathologist. Scores were based on an inflammation scale 1-5 (minimal, mild, moderate, marked, severe); maturation of bone (based on fibroblast infiltration, collagen deposition and myelofibrosis with 1=most immature to 5=most mature) and the presence of new bone growth (scored qualitatively on a 1-5 scale)

**Figure 9.** Analysis of histology slides by image recognition software. Each histology slide (panel A) has digitized and divided into 16 regions. Visopharm software was trained to recognize bone (green), cartilage (blue) and fibrous material (red) (Panel B). Mean values ( $\pm$ SD) for cartilage (C) and bone (D) are plotted. SFT = Salmon fibrinogen/thrombin, PFT = porcine fibrinogen/thrombin, BC = Bovine collagen and BF = CopiOS bone filler.

**Figure 10.** Prothrombin times for 19 animals sampled from Day 0 throughout the treatment period. Asterisks mark two samples from animals treated with PFT with lower than average values. Both animals had normal values on subsequent assays.

## Table legends

Table 1 Changes in RNA expression for bone-associated proteins in human mesenchymal stem cells at 7-day incubation. Cells were grown in differentiation medium or maintenance medium in the presence of salmon fibrinogen/thrombin. RNA was recovered from the cell samples and RNA expression was quantitated by RT-PCR. Values are expressed as the ratio of baseline expression in undifferentiated cells grown in maintenance media compared to cells grown in the specified condition. 7-Day diff = 7 day incubation with Celprogen differentiation media; Fibrin 1 = salmon fibrinogen 5mg/mL, salmon thrombin 10U/mL; Fibrin 2 = salmon fibrinogen 50mg/mL, salmon thrombin 10U/mL and Fibrin 3 = 50mg/mL, salmon thrombin 100U/mL

Table 2. Proteins showing increased RNA association during growth on various substrates with different media after 21 days. Cells were grown in differentiation medium or maintenance medium in the presence of salmon fibrinogen/thrombin. RNA was recovered from the cell samples and RNA expression was quantitated by RT-PCR. Values are expressed as the ratio of baseline expression in undifferentiated cells grown in maintenance media compared to cells grown in the specified condition. Dif. = 21 day incubation with Celprogen differentiation media; Fibrin 1 = salmon fibrinogen 5mg/mL, salmon thrombin 10U/mL; Fibrin 3 = salmon fibrinogen 50mg/mL, salmon thrombin 100U/mL. Collagen = Greiner Bio-One collagen coated flasks.

## Corresponding Authors



Stephen W. Rothwell, PhD is a Professor in the Department of Anatomy, Physiology and Genetics at the Uniformed Services University of the Health Sciences in Bethesda, MD. He is a member of the American Hematology Society with a longtime interest in hemostasis, coagulation, and platelet physiology. Recent projects have led him into investigations of the role of fibrinogen and clotting in the bone healing process and the proteomics of the clotting pathway.


Department of Anatomy, Physiology and Genetics Rm. B2026  
Uniformed Services University of the Health Sciences  
4302 Jones Bridge Road  
Bethesda, MD 20814-4799  
[srothwell@usuhs.mil](mailto:srothwell@usuhs.mil)







Timothy Settle, DVM, ACVPM, ACLAM is the Director of The Center for Laboratory Animal Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD. He formerly served as an 18C and Group Veterinarian, deploying most recently in support of CJSOTF Afghanistan.






Joseph Royal, DVM, MPH, ACVPM is the Deputy Director of The Center for Laboratory Animal Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD. He previously served as 10<sup>th</sup> Group Veterinarian and deployed to IRAQ.








**A****B****C**






**A****Wound fill****B****Callus formation**


## Bone densities




### A New bone formation







### B Mature bone



### C Inflammation







**A Comparison of Postoperative Analgesic Effects of  
Ultrasound-guided Regional Anesthesia in a Swine Femur  
Fracture Model**

Journal:	<i>Journal of the American Association for Laboratory Animal Science</i>
Manuscript ID:	JAALAS-12-000101
Manuscript Type:	Original Research
Date Submitted by the Author:	04-Sep-2012
Complete List of Authors:	Royal, Joseph; Uniformed Services University of the Health Sciences, Department of Laboratory Animal Medicine Settle, Timothy; Uniformed Services University of the Health Sciences, Department of Laboratory Animal Medicine Bodo, Michael; Naval Medical Research Center, ; Uniformed Services University of the Health Sciences, Department of Anatomy, Physiology, and Genetics Lombardini, Eric; Armed Forces Radiobiology Research Institute, Division of Comparative Pathology Kent, Michael; Walter Reed National Military Medical Center, Department of Anesthesiology Upp, Justin; Walter Reed National Military Medical Center, Department of Anesthesiology Rothwell, Stephen; Uniformed Services University of the Health Sciences, Department of Anatomy, Physiology, and Genetics
Keywords:	Swine < Animal species, Analgesics < Drugs/Pharmaceuticals, Analgesia < Animal management and use, Pain < Animal management and use, Pathology < Miscellaneous

SCHOLARONE™  
Manuscripts

1                   3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

3/5/2012 1:14 PM

1                   **Title:**                   **A Comparison of Postoperative Analgesic Effects of**  
2                   **Ultrasound-guided Regional Anesthesia in a Swine Femur**  
3                   **Fracture Model**

4                   **Authors:**                   **Joseph M Royal<sup>1,\*</sup>, Timothy L Settle<sup>1</sup>, Michael Bodo<sup>2,3</sup>, Eric**  
5                   **Lombardini<sup>4</sup>, Michael L Kent<sup>5</sup>, Justin Upp<sup>5</sup>, and Stephen W**  
6                   **Rothwell<sup>3</sup>**

7                   **Institutional affiliations:**                   **<sup>1</sup>Center for Laboratory Animal Medicine, Uniformed Services**  
8                   **University of the Health Sciences, Bethesda, Maryland; <sup>2</sup>Naval**  
9                   **Medical Research Center, Silver Spring, Maryland;**  
10                   **<sup>3</sup>Department of Anatomy, Physiology, and Genetics,**  
11                   **Uniformed Services University of the Health Sciences,**  
12                   **Bethesda, Maryland; <sup>4</sup>Division of Comparative Pathology,**  
13                   **Armed Forces Radiobiology Research Institute, Bethesda, MD;**  
14                   **<sup>5</sup>Department of Anesthesiology, Walter Reed National Military**  
15                   **Medical Center, Bethesda, Maryland.**

16                   **\*Corresponding author:**                   **Email: jroyal@usuhs.edu**

17                   **Running head:**                   **Ultrasound-guided regional anesthesia in swine**

18                   **Abbreviation:**                   **VAS, visual analog scale**

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 22 Abstract

23 Management of pain in research swine used for studies involving painful procedures is a  
24 significant challenge. This study assessed whether a regional anesthesia method is effective for  
25 pain control of hindlimb injuries in pigs used for research in bone fracture healing. For this  
26 randomized controlled study, we administered regional anesthesia before an experimental femur  
27 injury was produced. Using ultrasound guidance, we placed sterile infusion catheters near the  
28 sciatic and femoral nerves for infusion of local anesthetic for the first 24 hours following  
29 surgery. We evaluated various behavioral and physiologic parameters to test the hypothesis that  
30 this method of regional anesthesia would provide superior analgesia compared to systemic  
31 analgesic medications alone. We also collected blood samples to evaluate serum levels of  
32 cortisol and fentanyl postoperatively. At the end of the study period, we collected sciatic and  
33 femoral nerves and surrounding soft tissues for histopathologic evaluation. Treatment animals  
34 had lower subjective pain scores compared to control animals. Control animals had an increased  
35 time to first feed consumption and required rescue analgesia earlier in the postoperative period  
36 than treatment animals. Ultrasound-guided regional anesthesia emerges as a viable and effective  
37 adjunct to systemic analgesics for providing pain control in swine with experimental femur  
38 fractures.

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

39 **Introduction**

40 Experimentally-induced injuries in research animals may cause pain that requires the use  
41 of analgesia to ensure the welfare of the animal and to avoid the profound physiologic effects of  
42 unalleviated pain that can confound research. A study at our institution used swine for an  
43 induced femur fracture model to study bone healing. Because of the potentially painful nature of  
44 such injuries and the extended follow up required, pain control was a significant concern.

45 Pain in research swine is often alleviated using systemic opioids. The most common  
46 opioid used in research swine is buprenorphine, a centrally-acting mixed opioid receptor  
47 agonist/antagonist, which derives most of its analgesic effect from its partial agonistic activity at  
48 the mu opioid receptor.<sup>16</sup> However, to achieve continuous analgesia, it is necessary to give  
49 multiple parenteral injections over the course of a day, which can be distressing to pigs. Another  
50 opioid analgesic that has been used in swine is fentanyl, a centrally-acting pure mu opioid  
51 receptor agonist, which can be administered transdermally. However, transdermal fentanyl  
52 absorption in the pig is highly variable and may not reliably achieve effective levels in the  
53 blood.<sup>20,32</sup> Non-steroidal anti-inflammatory drugs, such as meloxicam, act by inhibiting the  
54 cyclooxygenase enzymes, which are key components of inflammatory pain pathways.<sup>16</sup> These  
55 drugs may be delivered parenterally or orally. However, oral analgesics may be difficult to  
56 deliver reliably in swine and non-steroidal anti-inflammatory drugs alone may not provide  
57 sufficient analgesia for moderate to severe pain.<sup>16</sup> Furthermore, in addition to their analgesic and  
58 anti-inflammatory effects, NSAIDs can also affect renal function, platelet function, and the  
59 integrity of gastrointestinal mucosa, potentially affecting patient welfare and altering the  
60 outcomes of research.<sup>16</sup>

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

61 An alternative option for providing effective analgesia that can be administered with  
62 minimal stress to the animal is perineural infusion of a local anesthetic. Local anesthetics such as  
63 lidocaine or bupivacaine produce anesthesia by blocking the function of voltage-gated sodium  
64 channels in the neuronal cell membrane, thus inhibiting neuronal signal conduction.<sup>16</sup> In this  
65 way, they can produce different degrees of anesthesia, analgesia, and motor blockade in a  
66 localized area with minimal systemic effects. Perineural catheters allow administration of  
67 regional anesthesia over extended periods of time with minimal stress to the patient. These  
68 methods have seen much use in human patients, and constitute an effective option for  
69 postoperative pain control.<sup>28</sup>

70 Successful delivery of regional anesthetic treatments can be facilitated by the use of  
71 ultrasound imaging. Regional anesthesia and ultrasound-guided regional anesthesia have been  
72 extensively described in the biomedical literature, and many reviews of these techniques are  
73 available.<sup>8,9,28,33,40,42-44</sup> Ultrasound guided methods of regional anesthesia have demonstrated  
74 distinct advantages over methods such as blind injection or nerve stimulation. Reported  
75 advantages include increased success of the nerve block, less local anesthetic usage, faster  
76 procedure time, and faster onset.<sup>9,33,40</sup>

77 Regional anesthesia is commonly used for surgical procedures in veterinary  
78 patients.<sup>11,12,31,35,47</sup> Continuous or intermittent infusion of local anesthetics for postoperative or  
79 persistent pain in animals has also been reported.<sup>10,48,50</sup> Techniques for pre-procedural single  
80 injection ultrasound-guided and nerve stimulation-assisted regional anesthesia have been  
81 described in dogs.<sup>3,4,7,14</sup> Swine have been used as a model for evaluating complications of  
82 regional anesthesia, such as intraneuronal injection and systemic and localized toxicity due to local  
83 anesthetics.<sup>1,5,6,30,51,52</sup> However, there are no published studies in the literature on the use of

1                   3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

84         ultrasound for placement of peripheral perineural infusion catheters for treatment of  
85         postoperative pain in animals.

86                 Anesthesia-related studies in swine are scarce. Peripheral nerve regional anesthesia with  
87         or without ultrasound guidance for analgesia of painful injuries has not been reported in research  
88         pigs. There are few clinical trials in the literature describing pain assessment and control in  
89         pigs.<sup>17</sup> This is problematic given the common use of pigs as research models involving surgical  
90         procedures and the standards and legal requirements for alleviation of pain in laboratory animals.  
91         The development of advanced anesthetic techniques, such as the method we present here, can  
92         support advances in medical research while satisfying accepted animal welfare standards.

93                 All animals in our study received systemic opioids, including parenteral buprenorphine  
94         and transdermal fentanyl, and non-steroidal anti-inflammatory medications for postoperative  
95         analgesia. However, because of the nature of the injury, we recognized the need for highly  
96         effective analgesia in the postoperative period and considered regional anesthesia as a viable  
97         option. We decided to test the hypothesis that ultrasound-guided regional anesthesia as an  
98         adjunct to systemic analgesics would reduce the need for systemic analgesics and improve  
99         subjective pain scores compared to systemic analgesics alone for postoperative management of  
100        pain associated with femur fracture in research swine.

## 101       **Materials and Methods**

102                 This study was reviewed and approved by the Uniformed Services University of the  
103         Health Sciences IACUC and performed in accordance with the Animal Welfare Act and the  
104         *Guide for the Care and Use of Laboratory Animals*.<sup>21</sup> Our study evaluated 19 female Yorkshire  
105        swine (*Sus scrofa domestica*) that were being used in a study on bone healing.

1                   3/5/2012 1:14 PM  
2  
3  
4

5                   106         **Animals.** The pigs were obtained from a commercial source (Animal Biotech Industries,  
6                   107         Inc., Danboro, PA) from a herd that is free of pseudorabies, brucellosis, and *Salmonella*. All pigs  
7                   108         receive parenteral iron dextran supplementation at 3 days of age. The pigs were been vaccinated  
8                   109         for *Mycoplasma hyopneumoniae*, porcine circovirus type 2, swine influenza virus, *Bordetella*  
9                   110         *bronchiseptica*, *Erysipelothrix rhusiopathiae*, and *Pasteurella multocida*, and all received  
10                  111         anthelmintic treatment (ivermectin) prior to shipment. Pigs were shipped to our institution in  
11                  112         pairs and underwent physical examination by a veterinarian upon arrival at the facility. These  
12                  113         entry examinations included weight measurement, recording of vital signs (temperature, heart  
13                  114         rate, respiratory rate), and fecal flotation for endoparasites. All parasite examinations were  
14                  115         negative.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

                 116         **Housing and Husbandry.** Study animals were housed individually in pens in the large  
                 117         animal section of an AAALAC-accredited animal facility. Each pen measured approximately 2.3  
                 118         X 1.9 meters. Primary enclosures consisted of epoxy coated floors with hard rubber floor mats to  
                 119         provide a non-slip surface within each pen. Walls of primary enclosures consisted of epoxy  
                 120         coated concrete, chain link fencing, and stainless steel panels. Animals were provided water via  
                 121         an automatic watering system and fed a standard swine diet ad libitum. Primary enclosures were  
                 122         cleaned and sanitized twice daily by animal care staff. Each animal was allowed a minimum of 5  
                 123         days acclimation to the facility before use in the study.

                 124         **Operating Room.** A dedicated operating room was used for all surgical procedures. A  
                 125         Datex/Ohmeda S/5 Anesthesia Delivery Unit and vital sign monitoring system (Datex/Ohmeda;  
                 126         Bromma, Sweden) and an InSight Fluoroscan fluoroscopy machine (Hologic, Inc; Bedford, MA)  
                 127         were used for anesthetic monitoring and radiographic imaging of the injured limb, respectively.

1                   3/5/2012 1:14 PM  
2  
3  
4

128                 **Anesthesia and monitoring.** For analgesia, all pigs received a transdermal fentanyl  
129                 patch (50 µg/h) approximately one day prior to surgery (mean 21.3 h, SD 3.1 h). Hair was  
130                 removed from the skin over the dorsal trunk using a commercial depilatory agent (Nair®, Church  
131                 & Dwight Co., Inc, Princeton, NH). The site was then rinsed, dried, and wiped with isopropyl  
132                 alcohol before placing the fentanyl patch and applying a transparent film dressing (Tegaderm  
133                 Film™, 3M, St Paul, MN) over the patch. On the day of surgery, all animals were premedicated  
134                 for anesthesia with tiletamine-zolazepam (Telazol©) 6 mg/kg IM in the neck. They were then  
135                 intubated and maintained on isoflurane anesthesia for the duration of the procedure. All animals  
136                 were maintained on an IV infusion of lactated ringer's solution at a rate of approximately 10  
137                 mL/kg/h, and a closed urine collection system was used for the duration of the procedure. A  
138                 trained anesthesia technician monitored and recorded intraoperative parameters, including  
139                 electrocardiography, pulse oximetry, capnography, bispectral index, inspired isoflurane  
140                 concentration, respiratory rate, body temperature, non-invasive blood pressure, and anesthetic  
141                 depth.  
142  
143  
144  
145  
146  
147

142                 **Regional anesthesia administration.** Prior to surgery, one animal from each pair was  
143                 randomly assigned to the treatment (bupivacaine) group and the other to the control (saline)  
144                 group in a blinded randomized controlled trial design. Once the animals were anesthetized, we  
145                 used ultrasound guidance to locate the sciatic nerve as it exits the pelvis thru the greater sciatic  
146                 foramen in the parasacral region and the femoral nerve in the proximal inguinal region. The skin  
147                 over each site was marked for reference.

148                 After antiseptic preparation and sterile draping of the right dorsal parasacral area, the  
149                 ultrasound probe was placed in a sterile sleeve and applied to the injection site with sterile  
150                 ultrasound gel. After identifying the sciatic nerve, a 17 gauge 9 cm Tuohy needle was inserted in

1           3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

151 plane with the probe with a short axis view of the nerve. With ultrasound visualization, the  
152 needle was advanced until it was immediately adjacent to the nerve. A syringe containing 10 mL  
153 of either 0.5% bupivacaine (treatment group) or 0.9% sodium chloride (control group) was  
154 attached to the hub of the needle, and after aspirating and confirming the absence of blood, 1 mL  
155 was injected. If the ultrasound image showed proper placement of the injected fluid, the  
156 remaining volume was infused while observing the ultrasound image. A 19 gauge closed tip  
157 multi-orifice polyamide infusion catheter (Perifix® or Contiplex® Tuohy Set, B. Braun,  
158 Germany) was then threaded through the Touhy needle, and held in place while the needle was  
159 retracted. The catheter was secured in place using tissue adhesive and transparent adhesive  
160 dressings with an accessible injection port.

161           For the femoral nerve, a short axis view of the nerve was obtained in the inguinal area as  
162 far cranial as possible. After antiseptic preparation and draping of the lateral flank, the Tuohy  
163 needle was introduced through the skin of the lateral ventral flank area cranial to the thigh and  
164 directed medially and caudally in plane with the ultrasound probe towards the site of interest,  
165 where the femoral nerve exits the inguinal canal. Local anesthetic (0.5% bupivacaine) or saline  
166 (10 mL) was then infused and the infusion catheter was placed and secured, as described for the  
167 sciatic nerve.

168           For ultrasound guidance of catheter placement, we used a model DP-6600Vet Universal  
169 UMS 700 Digital Ultrasonic Diagnostic Imaging System with a 7.5 megahertz linear transducer  
170 (Universal Medical Systems, Inc., New York). We also used a Stimuplex HNS12 peripheral  
171 nerve stimulator (B Braun, Germany) with the first four subjects to confirm accuracy of  
172 ultrasound in localization of the nerves of interest.

1                   3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

173                 **Injury.** Following application of regional anesthesia and aseptic preparation of the right  
174                 lateral thigh, femurs were pre-stabilized using an external fixation device. A right-side midshaft  
175                 femoral fracture was then produced using a captive bolt device on the lateral aspect of the thigh.  
176                 All fractures were evaluated radiographically immediately following injury. The degree of injury  
177                 was generally consistent across groups with penetration of both cortices and fragmentation  
178                 around the fracture site. After evaluation, the limb and fixation device were covered with a  
179                 protective cast.

180                 **Postoperative monitoring and analgesia.** Following surgery and prior to recovery from  
181                 anesthesia, all pigs received one dose of buprenorphine 0.05 mg/kg IM and one dose of  
182                 meloxicam 0.4 mg/kg SC. Repeat doses of bupivacaine (0.25%, 10 mL at each site) or the same  
183                 volume of sterile saline were then administered at 6-8 hour intervals for the first 24 hours  
184                 postoperatively, after which the pig was sedated with a combination of ketamine 10 mg/kg and  
185                 xylazine 2 mg/kg given IM, and the perineural catheters were removed. In all, 4 doses of local  
186                 anesthesia/saline control were administered: one dose preoperatively and 3 doses  
187                 postoperatively.

188                 Following full recovery from anesthesia on the day of surgery, pigs were monitored  
189                 frequently with full evaluations at least every 6-8 hours in the first 24 hours post-surgery. Pigs  
190                 were subjectively assessed by a clinical veterinarian to determine if pain levels merited rescue  
191                 analgesia (buprenorphine 0.05-0.1 mg/kg IM). Feed was offered immediately following full  
192                 recovery from anesthesia, and time to first consumption of any feed was recorded. We also  
193                 evaluated several pain indicators pre- and postoperatively, including heart rate as measured by  
194                 direct cardiac auscultation, respiratory rate by observation, and subjective pain assessment.<sup>16,17,22</sup>  
195                 Activity levels were estimated using a remote telemetry monitoring system (Data Sciences

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

196 International, St Paul, MN), which counted physical movements by the subjects starting the day  
197 prior to surgery through the fourth postoperative day.

198 To obtain baseline measurements, all evaluations were performed at two time points  
199 preoperatively: once before and once after placement of a transdermal fentanyl patch (Figure 1).  
200 Evaluations were then repeated at 3 time points on the day of surgery: 2 and 4 hours after  
201 recovery from anesthesia and again the night following surgery (approximately 10-11 hours post-  
202 surgery). Each pig was then evaluated twice daily for the next four days: once each morning  
203 (AM) and once each afternoon (PM). Additionally, each pig was weighed prior to surgery and  
204 weekly thereafter.

205 Five categories of subjective pain indicators were scored using a modified visual analog  
206 scale (VAS): Passive observation of the animal from outside its enclosure before entering  
207 (VAS1, Observation), strength and character of response to physical contact when placing a hand  
208 on the side of abdomen (VAS2, Contact), impairment of ability or of willingness to ambulate  
209 (VAS3, Ambulation), nature and intensity of vocalization (VAS4, Vocalization), and an overall  
210 subjective assessment of pain level after completing the full evaluation (VAS5, Overall). The  
211 VAS chart consisted of a 100 mm horizontal line for each category. After assessing the animal,  
212 the evaluator placed a mark on the line according to the assessed level of pain, with pain scores  
213 increasing from left to right on the scale (Figure 2). The VAS score was then derived by  
214 measuring the distance of the mark in millimeters from the left side of the scale. In all cases, a  
215 higher score indicated more severe impairment or pain.

216 All personnel involved in the study were blinded to treatment. Ninety percent of  
217 evaluations were performed by one individual. In cases where other evaluators were used, each  
218 pair of animals was evaluated by the same individual.

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

219       **Blood sampling and analyses.** Blood samples were collected from the left femoral vein  
220 under anesthesia intraoperatively and under heavy sedation at approximately 24 hours post-  
221 surgery to measure serum levels of cortisol and fentanyl. Blood samples were also taken under  
222 sedation one week after surgery to measure serum fentanyl levels.

223       Serum cortisol levels were measured using a commercially available porcine cortisol  
224 ELISA kit (Novatein Biosciences, Cambridge, MA). Serum fentanyl was measured using a  
225 competitive direct ELISA kit (BQ Kits, San Diego, CA). All assays were conducted according to  
226 manufacturer instructions.

227       Hematology and serum biochemistry data obtained at a commercial reference laboratory  
228 were analyzed for changes consistent with pain or distress, such as hyperglycemia or altered  
229 neutrophil to lymphocyte ratios. We also analyzed serum chemistry data for indirect signs of  
230 pain, such as physiologic indicators of dehydration (azotemia, hyperalbuminemia, increased  
231 hematocrit, hyperosmolality) due to decreased water intake. Total serum protein was measured  
232 using a clinical refractometer.

233       **Histopathology.** At three weeks post-surgery, all animals were euthanized and  
234 necropsied for collection of peripheral nerves and surrounding soft tissue for histopathological  
235 analysis. Bilaterally, 5 cm portions of both the femoral and sciatic nerves were dissected away  
236 along with surrounding skeletal muscle for evaluation. Tissue samples were fixed in 10%  
237 buffered formalin, paraffin wax-embedded, sectioned at approximately 5  $\mu\text{m}$ , and submitted to  
238 the Armed Forces Radiobiology Research Institute Division of Comparative Pathology for  
239 evaluation. Sections were routinely stained with hematoxylin and eosin and examined by light  
240 microscopy in a blinded manner for histopathological evaluation by a board-certified veterinary  
241 pathologist. Sections were evaluated for any pathological change within the peripheral nervous

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

242 system and surrounding soft tissues, with specific emphasis on degenerative or inflammatory  
243 changes within nerves.

244 **Statistical analysis.** We evaluated data graphically for normality and used Student's t-  
245 test to compare means or the Mann-Whitney U test to compare medians, as appropriate, for  
246 continuous independent variables. For data with repeated measures, we used Student's t-test with  
247 no adjustment for multiple comparison to compare preoperative time points and postoperative  
248 time points outside the expected period of analgesia (i.e., day 2 and beyond). We used a linear  
249 mixed effects model to compare overall differences between treatment groups and differences  
250 between treatment groups over time during the treatment period (i.e., day 0 and day 1). When the  
251 main effect of group and/or the group by time interaction were significant in the mixed model,  
252 individual time points were compared using Student's t-test with no adjustment for multiple  
253 comparisons. We used the log rank test and Kaplan-Meier curves to compare data measuring  
254 time to an event, and estimated hazard ratios using Cox proportional hazards regression.

255 Physical activity data were collected and processed using the DSI Ponema Physiology  
256 Platform (DSI Ponema, Valley View, OH). Telemetry data containing counts of physical  
257 movements were then divided into 12 hour segments corresponding to the light (7:00 AM to 7:00  
258 PM) and dark (7:00 PM to 7:00 AM) phase of the room light schedule. Total counts per hour for  
259 each segment were calculated and then compared between treatment and control groups using a  
260 linear mixed effects model as described above.

261 Statistical software packages were used to perform all statistical analyses (IBM SPSS  
262 Statistics Version 19, Chicago, IL) and to create graphs of study data (GraphPad Prism 6, San  
263 Diego, CA). Unless otherwise indicated, data are expressed as mean (+/SEM). All differences

1                   3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

3/5/2012 1:14 PM

264       were considered significant if the two-tailed p value was less than 0.05. As this study was  
265        appended to an ongoing study, sample size was predetermined by the needs of the parent study.

## 266       **Results**

267           Three pigs were removed from the study early. Two of these (one treatment and one  
268       control) were euthanized early due to inadequate stabilization of the femur fracture. Another pig  
269       in the treatment group expired in the immediate post-anesthetic period due to apparent  
270       laryngospasm following endotracheal tube removal. The control group had a significantly higher  
271       heart rate at the time of pre-study physical examination (Table 1). Weight, temperature, and  
272       respiratory rate did not differ significantly. No difference was observed in pain control between  
273       the initial 4 subjects in which nerve electrostimulation was used and the remaining subjects in  
274       which ultrasound alone was used for catheter placement.

275           Each animal was evaluated on how soon after surgery they began eating and defecating.  
276           The median (+/-standard error of the median) time at which the animals in each group ate their  
277       first meal was 4 (+/-0.37) hours for the treatment group and 11 (+/-5.0) hours for the control  
278       group (Figure 3). Median time to first defecation was 4.0 (+/-1.4) hours for the treatment group  
279       and 19 (+/-3.3) hours for the control group (Figure 4).

280           At each evaluation, the evaluator determined whether or not the animal was in sufficient  
281       pain to merit rescue analgesia. The median time of first intervention was 28 (+/-22.6) hours for  
282       the treatment group and 11 (+/-10.4) for the control group. (Figure 5) When comparing total  
283       quantity of buprenorphine administered postoperatively, control subjects tended to receive  
284       greater quantities on average, although the difference did not achieve statistical significance  
285       (Figure 6).

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

286 No significant differences were observed in any of the VAS data collected preoperatively  
287 or beyond day 1 postoperatively. In the evaluation of day 0 and day 1 VAS scores, mean passive  
288 observation (VAS1) score differences were not statistically significant between groups ( $p=0.55$ )  
289 in the mixed effects model (Figure 7). Mean scores for response to contact (VAS2) were higher  
290 at all time points for the control group, and there was a significant difference in overall means  
291 between treatment groups ( $p=0.009$ ) in the mixed effects model. In the pairwise comparison, the  
292 difference achieved significance at 3 time points within the first 24 hours of surgery (Figure 8).  
293 Mean ambulation scores (VAS3) did not differ significantly between treatment groups ( $p=0.45$ )  
294 in the mixed effects model (Figure 9). Mean scores for vocalization (VAS4) were higher in the  
295 control group at most time points in the first 24 hours after surgery (Figure 10). However, the  
296 mixed model analysis did not show a statistically significant effect of treatment between groups  
297 ( $p=0.065$ ). In the overall pain level assessment score (VAS5), there was a significant difference  
298 between treatment groups in the mixed effects model ( $p=0.008$ ), and two time points differed  
299 significantly in the pairwise comparison (Figure 11). None of the VAS parameters showed a  
300 significant interaction between treatment and time in the mixed effects model.

301 **Physical examination parameters.** At each evaluation, heart rate was measured by the  
302 evaluator by cardiac auscultation with a stethoscope, and respiratory rate was measured by visual  
303 observation of thoracic movement. Heart rate decreased in the treatment group during the first 24  
304 hours after treatment while staying relatively constant in the control group (Figure 12). However,  
305 the average heart rate did not differ statistically between treatment groups overall ( $p=0.061$ ) or  
306 between groups over time ( $p=0.64$ ) in the mixed effects model.

1  
2  
3 307        3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The mean respiratory rate was higher in the control group during the first 24 hours post-surgery (Figure 13). However, in the mixed effects model, the differences between treatment groups ( $p=0.18$ ) and between groups over time ( $p=0.25$ ) were not significant.

Activity levels, estimated by frequency of physical movements or motion measured telemetrically in the postoperative period, dropped sharply following surgery relative to preoperative levels. Activity levels then fluctuated on a regular circadian basis, with higher activity levels during the day and lower levels at night (Figure 14). While activity levels tended to be slightly higher in the control group, we did not observe a significant effect of treatment ( $p=0.84$ ) or a significant interaction between treatment and time ( $p=0.99$ ) in the mixed effects model.

**Clinical pathology.** Serum biochemistry values did not differ between treatment groups (Table 2). Of the hematology parameters measured, RBC count, hemoglobin, and hematocrit measured at 24 hours were all significantly elevated in the control group (Table 3). Blood samples were collected for serum fentanyl measurement at 3 approximate time points: 24, 48, and 72 hours following application of a transdermal fentanyl patch (Figure 15). The mean values (+/-SEM) at each respective time point were 0.31 (+/-0.070) ng/mL, 0.21 (+/-0.045) ng/mL, and 0.12 (+/-0.023) ng/mL. There were no significant differences between treatment and control groups in mean fentanyl levels at any of the time points.

**Histopathology.** Histopathological examination of all submitted tissues revealed an interesting mix of lesions in both saline and bupivacaine cohorts. These included examples of degenerative lesions of peripheral nerves (Figure 16) and lesions of skeletal muscle (Figure 17).

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

328 Within the saline cohort, 89% of the animals showed histopathological evidence of  
329 pathology in at least one of the sampled nerves. Of these animals, 75% had right sided  
330 pathology, 75% had left sided pathology, and 62.5% showed bilateral lesions. Within the  
331 bupivacaine cohort, 62.5% of the animals displayed nerve fiber pathology, of which 100% had  
332 right sided lesions and 25% had bilateral lesions. However, none of these differences achieved  
333 statistical significance.

## 334 Discussion

335 This study provides substantial evidence for a beneficial effect of regional anesthesia in  
336 addition to traditional systemic analgesics for hindlimb pain in swine. Most notably, untreated  
337 animals required rescue analgesia earlier following surgery than did treated animals.  
338 Furthermore, treated animals ate food and defecated earlier in the postoperative period than their  
339 untreated counterparts. As anorexia and decreased bowel function may occur with pain in  
340 animals, these differences provide evidence for an analgesic effect of the treatment. The  
341 observed effect on time to defecation may also be a result of greater inhibition of bowel function  
342 in control animals because they received more postoperative opioid analgesics, which are known  
343 to decrease motility and increase transit time in the gastrointestinal tract.<sup>16</sup>

344 Subjective pain assessment results in some categories also suggest a beneficial effect of  
345 the treatment. Control animals had higher pain scores despite the fact they tended to receive  
346 rescue analgesia sooner than treatment animals. The response to physical contact (VAS2) and the  
347 overall assessment of pain levels following examination (VAS5) appeared to best discriminate  
348 between treatment groups. In addition to demonstrating a positive effect of the regional

1           3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

349 anesthetic treatment, this shows that a subjective assessment that includes the response to  
350 physical contact may be helpful in assessing pain in swine.

351         VAS score trends over time are also consistent with the expected time course of the  
352 regional anesthesia effects. Scores tended to be very similar between treatment groups at the first  
353 postoperative evaluation (2 hours post-surgery). At that time point, it might be expected that the  
354 residual effects of anesthesia and postoperative analgesics either controlled pain adequately or  
355 resulted in sufficient sedation to mask the effects of pain as assessed by the subjective observer.  
356 However, starting at the next time point (4 hours post-surgery), VAS scores in the control group  
357 tend to be higher than in the treatment group, suggesting better pain control in the treatment  
358 group. This difference persists thru the treatment period and then disappears somewhere between  
359 8 and 24 hours after the last treatment was given, as would be expected given the typical duration  
360 of effect of bupivacaine. This time trend is readily apparent for response to contact, vocalization,  
361 and overall pain score. However, it is much less pronounced for simple observation from outside  
362 the cage, and is completely absent for ambulation scores.

363         It is noteworthy that simple observation of the animal from outside the pen—a common  
364 practice for pain assessment in laboratory animals—failed to detect any difference between  
365 treatment groups. Furthermore, while ability to ambulate improved significantly in both groups  
366 over time, it did not differ between treatment groups, suggesting this parameter may not be a  
367 reliable indicator of pain control in this model. It may also be that cast material on the legs  
368 impeded ambulation sufficiently in both groups to obscure any pain-related differences in  
369 ambulation. It is also possible that ambulation was inhibited by impairment of motor function in  
370 the treated limb due to the regional anesthesia, though this was not assessed in the study.

1                   3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

371                 At the time of initial entry into the facility prior to any experimental manipulation,  
372                 average heart rate on physical examination was higher in the pigs that would form the control  
373                 group than those in the treatment group. However, there were no other indications of baseline  
374                 differences between treatment and control groups. Furthermore, after acclimation to the facility,  
375                 subsequent pre- and postoperative examinations showed no significant difference in heart rate  
376                 between groups. In light of this, we believe this initial difference represents random variation in  
377                 conditions and not any true baseline difference between groups.

378                 Postoperative heart rates and respiratory rates measured during physical examination did  
379                 not differ significantly between treatment groups. However, a trend for decreased heart rate was  
380                 noted in the treatment group for about the first 24h post-surgery. This decrease in heart rate may  
381                 be a result of decreased activity due to immobility, a direct effect of bupivacaine on heart  
382                 function, or decreased pain.

383                 We also analyzed various clinical laboratory parameters as indirect indicators of  
384                 postoperative pain. Erythrocyte measures (RBC count, hematocrit, and hemoglobin) differed  
385                 between groups at the 24-hour postoperative time point, with slightly lower indices in the  
386                 treatment group. Changes in erythrocyte indices may occur with changes in hydration, which  
387                 may be occur if water intake is decreased due to pain. While the small difference observed in our  
388                 study could be explained by hemoconcentration in the control group due to unapparent  
389                 dehydration, evaluation of blood chemistry values (e.g., serum Na, Cl, K, BUN, creatinine, and  
390                 total protein) and clinical status revealed no other indications of a difference in hydration  
391                 between groups. Furthermore, no significant difference between groups appeared in hematocrits  
392                 measured intraoperatively or at 1 week following surgery. This difference at 24 hours may

1           3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

393 represent random variation in RBC mass between the two groups, though we cannot rule out the  
394 possibility of a direct effect of the drug (bupivacaine) on red blood cells in these animals.

395         We measured serum cortisol as an indirect measure of pain-induced sympathetic nervous  
396 system stimulation.<sup>18,39</sup> Cortisol levels did not differ significantly between the treatment and  
397 control groups. This may be due to lack of sensitivity of the assay, effects of handling and  
398 sedation for blood collection, or high stress in both groups due to immobility and handling.  
399 Furthermore, factors unrelated to pain may also affect these measurements. For example, cortisol  
400 may be altered with distress due to handling and is subject to circadian variation.<sup>26</sup> Samples were  
401 collected at a uniform time of day to avoid any effects of circadian variation, and all animals  
402 were sedated in a uniform manner to avoid introducing variation into blood value data. However,  
403 no reference range is available for serum cortisol in swine, and levels vary with age, weight, sex,  
404 feed consumption, environment, and handling, making absolute levels difficult to interpret.<sup>15,23,38</sup>  
405 Furthermore, since we did not measure preoperative baseline cortisol levels, we cannot  
406 determine if the cortisol levels observed postoperatively represented stress-induced elevations.

407         Blood glucose levels did not differ significantly between treatment and control groups in  
408 our study. This may suggest that blood glucose is an insensitive measure of pain in swine.  
409 However, blood glucose levels can be transiently affected by stress, fear, pain, feed consumption,  
410 and the use of sedatives.<sup>13,25,37</sup> Therefore, it is also possible any stress induced alterations in  
411 blood glucose could have been obscured by differences in feed consumption. The treatment  
412 group tended to have a shorter time to feed consumption post-surgery. However, the amount of  
413 feed consumed was not quantified, so the degree to which feeding differences may have altered  
414 blood glucose levels cannot be determined.

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

415 We measured serum fentanyl levels to ensure that the analgesic effect was similar  
416 between groups and to evaluate whether transdermal fentanyl delivery resulted in consistently  
417 adequate analgesic levels for 72 hours. Our measured serum fentanyl levels were similar to those  
418 of other studies. For example, one study evaluated transdermal fentanyl (50 µg/h) in Yorkshire-  
419 Landrace pigs and reported serum fentanyl levels at 24 hours of 0.47 ng/mL (range 0.17-1.0),  
420 with peak concentrations occurring at around 12-24 hours.<sup>32</sup> In another study of transdermal  
421 fentanyl (100 µg/h) in Yucatan minipigs, plasma fentanyl concentration peaked within 48 hours,  
422 with peak concentrations ranging from 0.38 to 0.99 ng/ml.<sup>49</sup> The authors of that study postulated  
423 based on extrapolation from other species that therapeutic plasma fentanyl levels in the pig may  
424 reasonably be assumed to fall within the approximate range of 0.2 to 3.0 ng/mL. If we assume  
425 the conservative end of this estimate (0.2 ng/mL), then 50%, 64%, and 100% of the animals in  
426 our study were below therapeutic levels at 24, 48, and 72 hours, respectively. This finding places  
427 some doubt on the reliability of transdermal fentanyl delivery in swine.

428 Some of the histopathologic lesions observed in our study were similar to the findings of  
429 others. For example, one study found increased lymphocytic and granulocytic infiltration peri-  
430 and intraneurally within 6 hours of bupivacaine instillation in pigs.<sup>46</sup> In another study describing  
431 histopathologic changes in pigs 7 and 28 days after a 6 hour perineural infusion of bupivacaine,  
432 investigators observed perivascular accumulation of inflammatory cells, myocyte regeneration,  
433 calcific myonecrosis, fibrous scar tissue, and degenerative changes.<sup>51</sup> However, we found no  
434 statistically significant patterns of distribution between treatment and control groups or between  
435 left and right limbs. The prevalence of background lesions in the neural and perineural soft tissue  
436 may obscure any potential correlation between lesions and treatments. Consequently, it is not

1           3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

437 clear if the lesions were incidental or related to injection of fluid, presence of bupivacaine, the  
438 bone injury, or prolonged recumbency.

439         This study faces several limitations. The small sample size and relatively high variability  
440 in some parameters limits the power to detect significant differences. Another limitation involves  
441 the difficulty in evaluating pain in animals such as pigs.<sup>2</sup> For example, pigs commonly object  
442 strongly to human handling even in the absence of pain. This makes it difficult to discern  
443 whether avoidance, guarding, vocalization, or reactions to touch are indicators of pain or simply  
444 behavioral idiosyncrasies. Furthermore, depending on the nature and severity of pain, a pig may  
445 demonstrate increases or decreases in activity, movement, and responsiveness.<sup>16,17,22</sup> It may also  
446 be that some indicators of pain may be more sensitive than others, and some may only be  
447 detected in cases of severe or protracted pain or distress. Some analgesics, such as fentanyl and  
448 buprenorphine, can cause sedation, which may confound interpretation of behavioral signs of  
449 pain. Lastly, control animals received rescue analgesia earlier, which may have abrogated some  
450 of the differences in pain-related parameters. Even objective measures of pain are fraught with  
451 difficulty, since they may be altered by physiologic processes independent of pain. Heart rate, for  
452 example, may increase with painful stimuli, but many other non-painful factors can increase or  
453 decrease heart rate, including anesthesia, drugs, excitement, and hemodynamic status. This  
454 makes interpretation of such parameters problematic.

455         Another challenge for this study is confirming continual efficacy of the regional block. It  
456 is possible that after placement, the infusion catheter tip may migrate as the animal moves,  
457 resulting in some or all of the local anesthetic not reaching the desired site. If catheter migration  
458 occurred in some subjects, it could have artificially shortened the apparent duration of analgesia

1           3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

459   achieved. Ideally, repeat imaging of the catheter prior to its removal would have confirmed  
460   proper location throughout the treatment period.

461         The relative novelty of this procedure necessitates further research. Future studies may  
462   evaluate alternative local anesthetics, such as ropivacaine, or formulations containing  
463   vasoconstrictors, as these may reduce toxicity and increase the intensity and duration of local  
464   anesthetic blocks.<sup>29,35,45</sup> Other compounds may be investigated for use as adjuncts to local  
465   anesthetics in peripheral nerve blocks, including alpha-2 adrenergic agonists, opioids,  
466   benzodiazepines, or corticosteroids.<sup>36,41</sup> It may also be preferable to measure different behavioral  
467   or physiologic parameters to assess pain, such as quantified intensity and frequency of  
468   vocalization or neuroendocrine markers of pain.<sup>19,34</sup> Future studies may examine the use of  
469   continuous infusion devices to provide more stable regional anesthesia over time than can be  
470   achieved with bolus administration. It would also be useful to evaluate the efficacy of regional  
471   anesthesia treatment over a longer period of time and any histopathologic effects of prolonged  
472   infusion protocols.

473         This study makes several significant contributions to laboratory animal welfare. It  
474   presents a postoperative pain assessment method for use in swine, which may be adapted and  
475   improved for clinical or investigational pain assessment. Another important finding of this study  
476   is the potential inability of transdermal fentanyl to adequately and consistently control pain in  
477   this model. In light of this, we recommend that transdermal fentanyl not be used as a sole method  
478   of analgesia for moderate to severe pain in swine. Most importantly, our data support the  
479   hypothesis that ultrasound-guided regional anesthesia provides superior analgesia compared to  
480   systemic analgesics alone for management of pain in hindlimb injuries in swine. The temporal  
481   patterns of treatment effects fit well with expected values, with maximum differences observed

1                   3/5/2012 1:14 PM  
2  
3  
4

482   during the postoperative treatment period and disappearing between 8 and 24 hours after  
483   cessation of treatment, which is consistent with the known duration of effect of bupivacaine.<sup>27</sup> In  
484   conclusion, ultrasound-guided regional anesthesia represents a significant refinement in pain  
485   management in laboratory animals and may realize superior analgesia with fewer potential  
486   systemic effects, thus improving both animal welfare and the validity of research outcomes.

487

488   **Acknowledgements**

489         This research project was supported by funding from the US Army Military Research and  
490   Materiel Command, Ft. Detrick, MD (W81XWH-09-2-0179) and by the Uniformed Services  
491   University of the Health Sciences, Bethesda, MD (grants R0702A and CO22AA). We would like  
492   to thank the Department of Laboratory Animal Medicine veterinary and animal care staff for  
493   animal care support, Ms. K. Brady and Dr. D. Larsen for technical assistance, Dr C. Olsen for  
494   statistical consultation, SSgt E. Stewart and Mr. B. Johnson for their preparation of  
495   histopathological specimens, and Dr C Christensen for preparation of histopathologic images.

496   **Disclaimers**

497         The authors declare no competing interests. The views of the authors do not purport to  
498   reflect the position of the Uniformed Services University or the Department of Defense.

499

500   **References**

- 501   1.   **Altermatt FR, Cummings TJ, Auten KM, Baldwin MF, Belknap SW, Reynolds JD.** 2010.  
502   Ultrasonographic appearance of intraneural injections in the porcine model. Reg Anesth Pain  
503   Med **35**:203-206.

3/5/2012 1:14 PM

- 1  
2  
3 504 2. **Anil SS, Anil L, Deen J.** 2002. Challenges of pain assessment in domestic animals. *J Am Vet Med Assoc* **220**:313-319.  
4 505 3. **Benigni L, Corr SA, Lamb CR.** 2007. Ultrasonographic assessment of the canine sciatic nerve. *Vet Radiol Ultrasound* **48**:428-433.  
5 506 4. **Campoy L, Bezuidenhout AJ, Gleed RD, Martin-Flores M, Raw RM, Santare CL, Jay AR, Wang AL.** 2010. Ultrasound-guided approach for axillary brachial plexus, femoral nerve, and sciatic nerve blocks in dogs. *Vet Anaesth Analg* **37**:144-153.  
6 507 5. **Candela D, Louart G, Bousquet PJ, Muller L, Nguyen M, Boyer JC, Peray PA, Goret L, Ripart J, Lefrant JY, de La Coussaye JE.** 2010. Reversal of bupivacaine-induced cardiac electrophysiologic changes by two lipid emulsions in anesthetized and mechanically ventilated piglets. *Anesth Analg* **110**:1473-1479.  
7 508 6. **Chan VW, Brull R, McCartney CJ, Xu D, Abbas S, Shannon P.** 2007. An ultrasonographic and histological study of intraneuronal injection and electrical stimulation in pigs. *Anesth Analg* **104**:1281-1284.  
8 509 7. **Costa-Farre C, Blanch XS, Cruz JI, Franch J.** 2011. Ultrasound guidance for the performance of sciatic and saphenous nerve blocks in dogs. *Vet J* **187**:221-224.  
9 510 8. **Cowlishaw PJ, Scott DM, Barrington MJ.** 2012. The role of regional anaesthesia techniques in the management of acute pain. *Anaesth Intensive Care* **40**:33-45.  
10 511 9. **Delaunay L, Plantet F, Jochum D.** 2009. [Ultrasound and regional anaesthesia]. *Ann Fr Anesth Reanim* **28**:140-160.  
11 512 10. **Driessen B, Scandella M, Zarucco L.** 2008. Development of a technique for continuous perineural blockade of the palmar nerves in the distal equine thoracic limb. *Vet Anaesth Analg* **35**:432-448.  
12 513 11. **Duke T.** 2000. Local and regional anesthetic and analgesic techniques in the dog and cat: Part I, Pharmacology of local anesthetics and topical anesthesia. *Can Vet J* **41**:883-884.  
13 514 12. **Duke T.** 2000. Local and regional anesthetic and analgesic techniques in the dog and cat: Part II, Infiltration and nerve blocks. *Can Vet J* **41**:949-952.  
14 515 13. **Duncan JR, Prasse KW, Mahaffey EA.** 1994. *Veterinary laboratory medicine: clinical pathology*. Ames, IA: Iowa State University Press.  
15 516 14. **Echeverry DF, Gil F, Laredo F, Ayala MD, Belda E, Soler M, Agut A.** 2010. Ultrasound-guided block of the sciatic and femoral nerves in dogs: a descriptive study. *Vet J* **186**:210-215.  
16 517 15. **Fagundes A, Negrao J, da Silva R, Gomes J, de Oliveira Souza L, Fukushima R.** 2008. Environmental temperature and serum cortisol levels in growing-finishing pigs. *Braz J Vet Res anim Sci* **45**:136-140.  
17 518 16. **Fish RE, Brown MJ, Danneman PJ, Karas AZ editors.** 2008. *Anesthesia and Analgesia in Laboratory Animals*. San Diego: Academic Press.  
18 519 17. **Flecknell PA, Waterman-Pearson A editors.** 2000. *Pain Management in Animals*. London: W.B. Saunders.  
19 520 18. **Guay J.** 2006. The benefits of adding epidural analgesia to general anesthesia: a metaanalysis. *J Anesth* **20**:335-340.  
20 521 19. **Hargreaves KM.** 1990. Neuroendocrine markers of stress. *Anesth Prog* **37**:99-105.  
21 522 20. **Harvey-Clark CJ, Gilespie K, Riggs KW.** 2000. Transdermal fentanyl compared with parenteral buprenorphine in post-surgical pain in swine: a case study. *Lab Anim* **34**:386-398.  
22 523 21. **Institute for Laboratory Animal Research.** 2011. *Guide for the Care and Use of Laboratory Animals*. Washington (DC): The National Academies Press.  
23 524 22. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
24 525 23. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
25 526 24. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
26 527 25. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
27 528 26. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
28 529 27. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
29 530 28. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
30 531 29. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
31 532 30. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
32 533 31. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
33 534 32. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
34 535 33. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
35 536 34. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
36 537 35. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
37 538 36. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
38 539 37. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
39 540 38. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
40 541 39. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
41 542 40. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
42 543 41. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
43 544 42. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
44 545 43. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
45 546 44. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
46 547 45. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
47 548 46. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
48 549 47. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
49 550 48. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
50 551 49. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
51 552 50. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
52 553 51. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
53 554 52. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
54 555 53. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
55 556 54. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
56 557 55. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
57 558 56. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
58 559 57. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
59 560 58. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.  
60 561 59. **Institute for Laboratory Animal Research (U.S.). Committee on Recognition and Alleviation of Pain in Laboratory Animals.** 2009. *Recognition and alleviation of pain in laboratory animals*. Washington, D.C.: National Academies Press.

3/5/2012 1:14 PM

- 1  
2  
3 552 23. **Kadarmideen HN, Janss LL.** 2007. Population and systems genetics analyses of cortisol in pigs  
4 553 divergently selected for stress. *Physiol Genomics* **29**:57-65.  
5 554 24. **Kahn CM.** The Merck Veterinary Manual. Whitehouse Station, NJ: Merck & Co.  
6 555 25. **Kim MJ, Park CS, Jun MH, Kim MC.** 2007. Antagonistic effects of yohimbine in pigs  
7 556 anaesthetised with tiletamine/zolazepam and xylazine. *Vet Rec* **161**:620-624.  
8 557 26. **Klemcke HG, Nienaber JA, Hahn GL.** 1989. Plasma adrenocorticotropic hormone and cortisol in  
9 558 pigs: effects of time of day on basal and stressor-altered concentrations. *Proc Soc Exp Biol Med*  
10 559 **190**:42-53.  
11 560 27. **Lemke KA, Dawson SD.** 2000. Local and regional anesthesia. *Vet Clin North Am Small Anim Pract*  
12 561 **30**:839-857.  
13 562 28. **Liu SS, Ngeow JE, Yadeau JT.** 2009. Ultrasound-guided regional anesthesia and analgesia: a  
14 563 qualitative systematic review. *Reg Anesth Pain Med* **34**:47-59.  
15 564 29. **Liu SS, Salinas FV.** 2003. Continuous plexus and peripheral nerve blocks for postoperative  
16 565 analgesia. *Anesth Analg* **96**:263-272.  
17 566 30. **Lupu CM, Kiehl TR, Chan VW, El-Beheiry H, Madden M, Brull R.** 2010. Nerve expansion seen on  
18 567 ultrasound predicts histologic but not functional nerve injury after intraneuronal injection in pigs.  
19 568 *Reg Anesth Pain Med* **35**:132-139.  
20 569 31. **Mahler SP, Adogwa AO.** 2008. Anatomical and experimental studies of brachial plexus, sciatic,  
21 570 and femoral nerve-location using peripheral nerve stimulation in the dog. *Vet Anaesth Analg*  
22 571 **35**:80-89.  
23 572 32. **Malavasi LM, Augustsson H, Jensen-Waern M, Nyman G.** 2005. The effect of transdermal  
24 573 delivery of fentanyl on activity in growing pigs. *Acta Vet Scand* **46**:149-157.  
25 574 33. **Marhofer P, Schrogendorfer K, Koenig H, Kapral S, Weinstabl C, Mayer N.** 1997.  
26 575 Ultrasonographic guidance improves sensory block and onset time of three-in-one blocks.  
27 576 *Anesth Analg* **85**:854-857.  
28 577 34. **Marx G, Horn T, Thielbein J, Knubel B, von Borell E.** 2003. Analysis of pain-related vocalization  
29 578 in young pigs. *Journal of Sound and Vibration* **266**:687-698.  
30 579 35. **Muir WW, Hubbell JA, Bednarski RM, Skarda RT.** 2007. *Handbook of Veterinary Anesthesia, 4th  
31 580 Edition.* St. Louis: Mosby Elsevier.  
32 581 36. **Murphy DB, McCartney CJ, Chan VW.** 2000. Novel analgesic adjuncts for brachial plexus block: a  
33 582 systematic review. *Anesth Analg* **90**:1122-1128.  
34 583 37. **Nishimura R, Kim HY, Matsunaga S, Hayashi K, Tamura H, Sasaki N, Takeuchi A.** 1994. Effects of  
35 584 medetomidine-midazolam on plasma glucose and insulin concentrations in laboratory pigs. *J Vet  
36 585 Med Sci* **56**:559-561.  
37 586 38. **Perez MP, Palacio J, Santolaria MP, del Acena MC, Chacon G, Verde MT, Calvo JH, Zaragoza  
38 587 MP, Gascon M, Garcia-Belenguer S.** 2002. Influence of lairage time on some welfare and meat  
39 588 quality parameters in pigs. *Vet Res* **33**:239-250.  
40 589 39. **Prunier A, Mounier AM, Hay M.** 2005. Effects of castration, tooth resection, or tail docking on  
41 590 plasma metabolites and stress hormones in young pigs. *J Anim Sci* **83**:216-222.  
42 591 40. **Salinas FV.** 2010. Ultrasound and review of evidence for lower extremity peripheral nerve  
43 592 blocks. *Reg Anesth Pain Med* **35**:S16-25.  
44 593 41. **Thornton PC, Grant SA, Breslin DS.** 2010. Adjuncts to local anesthetics in peripheral nerve  
45 594 blockade. *Int Anesthesiol Clin* **48**:59-70.  
46 595 42. **Tsui B, Suresh S.** 2010. Ultrasound imaging for regional anesthesia in infants, children, and  
47 596 adolescents: a review of current literature and its application in the practice of extremity and  
48 597 trunk blocks. *Anesthesiology* **112**:473-492.  
49 598 43. **Tsui BC, Pillay JJ.** 2010. Evidence-based medicine: Assessment of ultrasound imaging for regional  
50 599 anesthesia in infants, children, and adolescents. *Reg Anesth Pain Med* **35**:S47-54.

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 600 44. **Tsui BC, Suresh S.** 2010. Ultrasound imaging for regional anesthesia in infants, children, and  
601 adolescents: a review of current literature and its application in the practice of neuraxial blocks.  
602 *Anesthesiology* **112**:719-728.
- 603 45. **Udelsmann A, Silva WA, Moraes AC, Dreyer E.** 2009. Hemodynamic effects of ropivacaine and  
604 levobupivacaine intravenous injection in swines. *Acta Cir Bras* **24**:296-302.
- 605 46. **Voelckel WG, Klima G, Krismer AC, Haslinger C, Stadlbauer KH, Wenzel V, von Goedecke A.**  
606 2005. Signs of inflammation after sciatic nerve block in pigs. *Anesth Analg* **101**:1844-1846.
- 607 47. **Wagner AE, Mama KR, Ruehlman DL, Pelkey S, Turner AS.** 2011. Evaluation of effects of sciatic  
608 and femoral nerve blocks in sheep undergoing stifle surgery. *Lab Anim (NY)* **40**:114-118.
- 609 48. **Watts AE, Nixon AJ, Reesink HL, Cheetham J, Fubini SL, Looney AL.** 2011. Continuous peripheral  
610 neural blockade to alleviate signs of experimentally induced severe forelimb pain in horses. *J Am  
611 Vet Med Assoc* **238**:1032-1039.
- 612 49. **Wilkinson AC, Thomas ML, 3rd, Morse BC.** 2001. Evaluation of a transdermal fentanyl system in  
613 yucatan miniature pigs. *Contemp Top Lab Anim Sci* **40**:12-16.
- 614 50. **Wolfe TM, Bateman SW, Cole LK, Smeak DD.** 2006. Evaluation of a local anesthetic delivery  
615 system for the postoperative analgesic management of canine total ear canal ablation--a  
616 randomized, controlled, double-blinded study. *Vet Anaesth Analg* **33**:328-339.
- 617 51. **Zink W, Bohl JR, Hacke N, Sinner B, Martin E, Graf BM.** 2005. The long term myotoxic effects of  
618 bupivacaine and ropivacaine after continuous peripheral nerve blocks. *Anesth Analg* **101**:548-  
619 554.
- 620 52. **Zink W, Seif C, Bohl JR, Hacke N, Braun PM, Sinner B, Martin E, Fink RH, Graf BM.** 2003. The  
621 acute myotoxic effects of bupivacaine and ropivacaine after continuous peripheral nerve  
622 blockades. *Anesth Analg* **97**:1173-1179.

623  
624  
625  
626  
627  
628  
629 **Figures and tables**  
630

631 Figure 1. Time line of study events. Asterisks (\*) indicate where boluses of either bupivacaine or  
632 saline were given.

633 Figure 2. VAS scoring sheet used for subjective pain level assessments. Evaluators were  
634 instructed to place a tic mark on the line at the most appropriate position along the line, using the

1                   3/5/2012 1:14 PM  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

635 descriptions in the boxes as guidelines. In general, the left side of the scale represents no pain,  
636 and the right side the highest level of pain.

637 Figure 3. Kaplan-Meier cumulative survival curve showing time in hours to first consumption of  
638 feed following surgery. Hazard ratio (95% CI): 4.4 (1.0 - 18.7). The curves differ significantly  
639 (p=0.048).

640 Figure 4. Kaplan-Meier cumulative survival curve showing time in hours to first bowel  
641 movement following surgery. Hazard ratio (95% CI): 5.0 (1.3 - 19.6). The curves differ  
642 significantly (p=0.021).

643 Figure 5. Kaplan-Meier cumulative survival curve showing time in hours to first administration  
644 of rescue analgesia following surgery. Hazard ratio (95% CI): 3.9 (1.0 - 14.7). The survival  
645 curves differ significantly (p=0.044).

646 Figure 6. Average total daily quantity of buprenorphine administered per animal on the day of  
647 surgery (Day 0) and each of the next 3 days post-surgery. Error bars: +/-1 SEM.

648 Figure 7. Mean VAS1 (Observation) scores by treatment group. Arrow represents last dose of  
649 local anesthetic/saline control. d0=day of surgery, d1= first day following surgery, etc. Error  
650 bars: +/-1 SEM.

651 Figure 8. Mean VAS2 (Contact) scores by treatment group. Arrow represents last dose of local  
652 anesthetic/saline control. Statistically different time points (Student's t test) are indicated with an  
653 asterisk. d0=day of surgery, d1= first day following surgery, etc. Error bars: +/-1 SEM.

654 Figure 9. Mean VAS3 (Ambulation) scores by treatment group. Arrow represents last dose of  
655 local anesthetic/saline control. d0=day of surgery, d1= first day following surgery, etc. Error  
656 bars: +/-1 SEM.

1  
2  
3 3/5/2012 1:14 PM  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

657 Figure 10. Mean VAS4 (Vocalization) scores by treatment group. Arrow represents last dose of  
658 local anesthetic/saline control. d0=day of surgery, d1= first day following surgery, etc. Error  
659 bars: +/-1 SEM.  
660 Figure 11. Mean VAS5 (Overall) scores by treatment group. Arrow represents last dose of local  
661 anesthetic/saline control. Statistically different time points (Student's t test) are indicated with an  
662 asterisk. d0=day of surgery, d1= first day following surgery, etc. Error bars: +/-1 SEM.  
663 Figure 12. Mean heart rate as measured by direct cardiac auscultation during physical  
664 examination. Arrow represents last dose of local anesthetic/saline control. Error bars: +/-1 SEM.  
665 Figure 13. Mean respiratory rate as measured by direct observation during physical examination.  
666 Arrow represents last dose of local anesthetic/saline control. Error bars: +/-1 SEM.  
667 Figure 14. Mean number of movements counted per hour during the day and night phases. Error  
668 bars: +/-1 SEM.  
669 Figure 15. Serum fentanyl levels in ng/mL by elapsed time in hours since placement of a  
670 fentanyl patch (50 µg/h). Boxes represent bupivacaine treated subjects and circles are saline  
671 controls. Blood sampling occurred at the following times in hours (mean +/- standard deviation)  
672 following fentanyl patch placement: first sampling at 21.1 +/- 2.5 hours, second sampling at 47.4  
673 +/- 3.5 hours, and third sampling at 73.2 +/- 2.7 hours.  
674 Figure 16. Right sciatic nerve of a bupivacaine-injected animal showing axonal degeneration and  
675 loss characterized by hyperchromatic condensation of the axons (arrows). Hematoxylin and  
676 eosin, magnification 600x.

3/5/2012 1:14 PM

1  
2  
3 677 Figure 17. Right femoral nerve of a bupivacaine-injected animal showing skeletal muscle with  
4 rhabdomyocytic atrophy and loss that is focally extensive and severe with abundant fibrosis.  
5  
6 678  
7  
8 679 Hematoxylin and eosin, magnification 400x.  
9  
10  
11 680  
12  
13  
14 681 Table 1. Pre-study physical examination data for all pigs separated by treatment group.  
15

Parameter	Treatment group	Mean +/- SEM	P value
Weight (kg)	Treatment	27.8 +/- 2.3	
	Control	28.2 +/- 2.8	0.90
Temperature (°C)	Treatment	38.9 +/- 0.10	
	Control	39.2 +/- 0.11	0.088
Heart rate (bpm)	Treatment	118.8 +/- 6.9	
	Control	151.3 +/- 11.0	0.020
Respiratory rate (breaths/minute)	Treatment	43.2 +/- 3.3	
	Control	50.7 +/- 3.3	0.12
Age (days)	Treatment	82.2 +/- 4.6	
	Control	82.4 +/- 5.2	0.97

42 682 n=10 for treatment, n=9 for control  
43  
44  
45 683  
46  
47  
48 684 Table 2. Serum chemistry data at 24 hour post-surgery.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Serum chemistry parameter	Treatment	N	Mean +/-SEM	p	range <sup>a</sup>	Reference
Sodium (mmol/L)	Bupivacaine	7	145.2 +/-4.7	0.43	142-149	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
3/5/2012 1:14 PM

	Saline	7	145.0 +/-1.0		
	Bupivacaine	7	100.3 +/-2.6		
Chloride (mmol/L)	Saline	7	101.3 +/-0.92	0.69	100-109
	Bupivacaine	7	96.3 +/-8.3		
Glucose (mg/dL)	Saline	7	113.3 +/-7.2	0.25	85-160
	Bupivacaine	7	7.6 +/-0.48		
BUN (mg/dL)	Saline	7	8.3 +/-0.65	0.24	6-30
	Bupivacaine	7	1.1 +/-0.081		
Creatinine (mg/dL)	Saline	7	1.2 +/-0.064	0.79	0.5-2.1
	Bupivacaine	8	5.0 +/-0.43		
Serum total protein (g/dL)	Saline	9	5.9 +/-0.33	0.11	6.1-7.5
	Bupivacaine	8	16.2 +/-0.72		
Cortisol (ng/mL)	Saline	9	17.1 +/-0.67	0.42	

685 <sup>a</sup>Reference ranges were provided by the commercial laboratory conducting the analyses; no  
 686 reference range has been established for cortisol in swine.

687  
 688 Table 3. Hematology results at 24 h post-surgery.

Parameter	Treatment	N	Mean+/- SEM	p	Reference range <sup>a</sup>
Hematocrit (%) <sup>b</sup>	Bupivacaine	6	27.4 +/-0.49		
	Saline	6	29.5 +/-0.50	0.011	36.9-55
RBC count (M/uL)	Bupivacaine	6	5.4 +/-0.082	0.024	5.5-8.2

3/5/2012 1:14 PM

		Saline	6	5.9 +/-0.14		
		Bupivacaine	6	8.9 +/-0.15		
	Hemoglobin (g/dL)				0.012	12.6-19.4
		Saline	6	9.6 +/-0.19		
		Bupivacaine	6	1.8 +/-0.84		
	N:L ratio <sup>c</sup>				0.91	0.7
		Saline	6	1.9 +/-0.56		

689 <sup>a</sup>Reference ranges were provided for all erythrocyte indices by the reference laboratory

690 conducting the analyses.

691 <sup>b</sup>Samples were collected at 24 hours into K<sub>3</sub>EDTA tubes from sedated subjects.

692 <sup>c</sup>N:L (Neutrophil to lymphocyte) ratio reference value was obtained from a reference text.<sup>24</sup>




Figure 1. Time line of study events. Asterisks (\*) indicate where boluses of either bupivacaine or saline were given.

608x263mm (96 x 96 DPI)




Figure 2. VAS scoring sheet used for subjective pain level assessments. Evaluators were instructed to place a tic mark on the line at the most appropriate position along the line, using the descriptions in the boxes as guidelines. In general, the left side of the scale represents no pain, and the right side the highest level of pain.

141x192mm (300 x 300 DPI)




Figure 3. Kaplan-Meier cumulative survival curve showing time in hours to first consumption of feed following surgery. Hazard ratio (95% CI): 4.4 (1.0 - 18.7). The curves differ significantly ( $p=0.048$ ).  
73x50mm (300 x 300 DPI)




Figure 4. Kaplan-Meier cumulative survival curve showing time in hours to first bowel movement following surgery. Hazard ratio (95% CI): 5.0 (1.3 - 19.6). The curves differ significantly ( $p=0.021$ ).  
73x51mm (300 x 300 DPI)




Figure 5. Kaplan-Meier cumulative survival curve showing time in hours to first administration of rescue analgesia following surgery. Hazard ratio (95% CI): 3.9 (1.0 - 14.7). The survival curves differ significantly ( $p=0.044$ ).  
73x50mm (300 x 300 DPI)




Figure 6. Average total daily quantity of buprenorphine administered per animal on the day of surgery (Day 0) and each of the next 3 days post-surgery. Error bars: +/- 1 SEM  
83x72mm (300 x 300 DPI)




Figure 7. Mean VAS1 (Observation) scores by treatment group. Arrow represents last dose of local anesthetic/saline control. d0=day of surgery, d1= first day following surgery, etc. Error bars: +/- 1 SEM.  
96x91mm (300 x 300 DPI)




Figure 8. Mean VAS2 (Contact) scores by treatment group. Arrow represents last dose of local anesthetic/saline control. Statistically different time points (Student's t test) are indicated with an asterisk.  
d0=day of surgery, d1= first day following surgery, etc. Error bars: +/- 1 SEM  
97x94mm (300 x 300 DPI)




Figure 9. Mean VAS3 (Ambulation) scores by treatment group. Arrow represents last dose of local anesthetic/saline control. d0=day of surgery, d1= first day following surgery, etc. Error bars: +/-1 SEM.  
97x94mm (300 x 300 DPI)




Figure 10. Mean VAS4 (Vocalization) scores by treatment group. Arrow represents last dose of local anesthetic/saline control. d0=day of surgery, d1= first day following surgery, etc. Error bars: +/-1 SEM.  
631x609mm (96 x 96 DPI)




Figure 11. Mean VAS5 (Overall) scores by treatment group. Arrow represents last dose of local anesthetic/saline control. Statistically different time points (Student's t test) are indicated with an asterisk.  
d0=day of surgery, d1= first day following surgery, etc. Error bars: +/- 1 SEM  
97x94mm (300 x 300 DPI)




Figure 12. Mean heart rate as measured by direct cardiac auscultation during physical examination. Arrow represents last dose of local anesthetic/saline control. Error bars: +/- 1 SEM  
647x609mm (96 x 96 DPI)




Figure 13. Mean respiratory rate as measured by direct observation during physical examination. Arrow represents last dose of local anesthetic/saline control. Error bars: +/- 1 SEM  
631x650mm (96 x 96 DPI)




Figure 14. Mean number of movements counted per hour during the day and night phases. Error bars: +/- 1 SEM.  
126x167mm (300 x 300 DPI)




Figure 15. Serum fentanyl levels in ng/mL by elapsed time in hours since placement of a fentanyl patch (50 µg/h). Boxes represent bupivacaine treated subjects and circles are saline controls. Blood sampling occurred at the following times in hours (mean +/- standard deviation) following fentanyl patch placement: first sampling at 21.1 +/- 2.5 hours, second sampling at 47.4 +/- 3.5 hours, and third sampling at 73.2 +/- 2.7 hours.

154x146mm (300 x 300 DPI)




Figure 16. Right sciatic nerve of a bupivacaine-injected animal showing axonal degeneration and loss characterized by hyperchromatic condensation of the axons (arrows). Hematoxylin and eosin, magnification 600x.

164x123mm (220 x 220 DPI)




Figure 17. Skeletal muscle in the area of the right femoral nerve of a bupivacaine-injected animal showing rhabdomyocytic atrophy and loss that is focally extensive and severe with abundant fibrosis. Hematoxylin and eosin, magnification 400x.  
1439x1083mm (72 x 72 DPI)

## **Noninvasive monitoring of healing from penetrating traumatic compound femur fracture in swine**

Michael Bodo<sup>1</sup>, Timothy Settle<sup>2</sup>, Joseph Royal<sup>2</sup>, Eric Lombardini<sup>3</sup>, Evelyn Sawyer<sup>4</sup> Stephen W. Rothwell<sup>1</sup>

### **Abstract**

The treatment of extremity combat wounds can be optimized with better information on the wound healing process. Here we present results gained by using non-invasive measurement modalities in an animal study. A comminuted femur fracture of the right hind leg was produced under anesthesia in 30 female Yorkshire swine, and one of four treatments was instilled into the wound immediately following injury (salmon fibrinogen/thrombin - n=8; commercial bone filler matrix, CopiOs - n= 7; bovine collagen – n=8, and porcine fibrinogen/thrombin - n=7). The fracture was stabilized with an external fixation device, and the animal was recovered. Blood samples were taken, and radiographic examination and measurement of physiological signals were conducted weekly for three weeks. Analog signals (near infrared spectroscopy, electrical bioimpedance, and blood flow by Doppler ultrasound flowmetry) were recorded on both hind legs at a frequency of 250 Hz and processed off-line. The mean values of ten second periods were used for left – right side comparison. ANOVA was used for statistical analysis. There was no significant difference between treatment groups for body weight, inflammation severity score, regional oxygenation, blood flow, and electrical bio-impedance. However, salmon fibrinogen/thrombin showed different time trends in measures of regional oxygenation compared to the other three treatments. For the salmon fibrinogen/thrombin treatment, the maximal laterality difference was observed after one week. Since all measured modalities reflect both wound healing as well as inflammation, the results need to be correlated with radiographic examination and blood sample analysis for final scoring of measured compounds. Based on our results, these non-invasive techniques may offer convenient quantification of wound healing in humans as well.

**Keywords** Femur fracture - Noninvasive monitoring - Near infrared spectroscopy - Blood flow – Bioimpedance

Contact: Dr. Stephen Rothwell  
Uniformed Services University of the Health Sciences, Bethesda, MD  
[stephen.rothwell@usuhs.edu](mailto:stephen.rothwell@usuhs.edu)

<sup>1</sup> Department of Anatomy, Physiology and Genetics, <sup>2</sup> Center for Laboratory Animal Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD;

<sup>3</sup> Armed Forces Radiobiology Research Institute, Bethesda, MD, <sup>4</sup> Sea Run Holdings, Freeport ME

## **1 Introduction**

Accidents or unintentional injuries ranked as the 5<sup>th</sup> leading cause of death in the United States in 2010 [1]. The nonfatal, construction industry-related injury rate was 410/10,000 [2]. Nearly 25% of adults involved in pedestrian accidents sustained tibia-fibular fractures [3]. Fifty nine percent of trauma center patients came from motor vehicle accidents [4]. Hospital stay, Injury Severity Score, Revised Trauma Score, Glasgow Coma Scale, and the mortality rate all worsen with increasing age [5]. Peak injury period and type of injuries were detailed elsewhere [6].

The epidemiology of military trauma was detailed previously by Bellamy et al, [7], and more recently by Holcomb et al, [8]. Recent U.S. conflicts have advanced the practice of vascular trauma surgery on the battlefield and offer important lessons learned for management of similar types of injury in urban trauma centers. Damage control techniques for complex injuries with associated hemodynamic instability may provide an opportunity to save both life and limb [9, 10].

Infection is a common complication of combat-related injuries [11]. Enhanced medical training of front line medical personnel, personal protective equipment, and the presence of far forward surgical assets have improved the initial survival of casualties in the current wars in Iraq and Afghanistan. As such, more casualties experience infectious complications of injuries including sepsis, which was a noted killer of casualties in previous wars. During the current conflicts, military personnel who develop combat-related injuries are at substantial risk of developing infections with multidrug resistant bacteria [12].

Here we present results of noninvasive monitoring of penetrating traumatic compound femur fracture in swine. Monitoring methods included the following modalities: 1) *Near infrared spectroscopy* (NIRS) which uses *in vivo* optical spectroscopy to provide real-time monitoring of changes in regional oxygen saturation ( $rSO_2$ ) of blood in the brain or other body tissues beneath the sensor [13]. 2) *Bio-impedance measurement or impedance plethysmography* which is a method for noninvasive measurement of volume and rate of blood flow. This technique relies on the proportional relationship between output signal amplitude (pulse wave) and the fluid content or conductive ion-containing volume within the tissues located between measuring electrodes [14, 15]. 3) *Doppler ultrasound flowmetry* was used to examine the blood flow pulse waves in the adjacent arteries.

Our hypothesis was that the wound, the treatment, and the healing process may alter blood flow,  $rSO_2$ , and tissue fluid volume.

## **2 Methods**

Under isoflurane anesthesia, the right femur was stabilized by an external fixation device and a limb injury with soft tissue damage and a comminuted femur fracture was then produced in 3-month-old female Yorkshire swine using a penetrating captive bolt as described by Majetschak , et al [16] (Figure 1). One of four treatments was delivered to the open fracture immediately following injury: (1) salmon fibrinogen and thrombin - SFT (Sea Run Holdings, Eastport, ME); n=8), (2) porcine fibrinogen and thrombin - PFT (Enzyme Research, Inc. South Bend, IN), ; n=7), (3) bovine collagen – BC (Sigma-Aldrich, St Louis, MI); n=7) and (4) CopiOS<sup>R</sup> Bone Void Filler (Distributor, Zimmer, Inc., Warsaw, IN; manufacturer, Kensey Nash Corp); n=7). The injury was dressed and the animal was recovered. Radiographic examination and blood sample collection were conducted weekly for three weeks. Post-mortem computed tomography (CT) examination of the femur was conducted following euthanasia to determine the level of bone development and ossification. The following measurements were performed before and immediately after surgery and then weekly thereafter: 1) NIRS using the INVOS<sup>®</sup> System

(Cerebral/Somatic Oximeter, Somanetics, Troy, MI); 2) *Bioimpedance* (BI) measurement using a Cerberus amplifier (Quintlab, Budapest, Hungary) with a 125 kHz measuring frequency using either 150 X 6 mm 3M M6001 electrode tape and electrode gel with; or SF405 ECG electrodes (Kendall, Medi-Care). 3) *Doppler ultrasound flowmetry* with a Model 812 Doppler flow detector with a 9.5 MHz infant flat probe (head size: 15 x 12 x 4 mm, Parks Medical Electronics, Inc., Aloha, OR) and Aquasonic 100 Ultrasound transmission gel (Parker Laboratories, Fairfield, NJ). Sensor and electrode locations are presented on Figure 2.

## 2. 1 Data processing

Measurements were made at the following time points: pre-surgery, post-surgery, one, two, and three weeks after surgery under isoflurane anesthesia with the swine in a supine position. Data (analog physiological signals) were digitized at 250 Hz and collected using the Ponemah Physiology Platform (Data Sciences International, St. Paul, MN). Data were processed with DataLyser, a software developed at the Walter Reed Army Institute of Research, Silver Spring, MD, for display, storage, and processing of analog physiological signals. NIRS values were used after stabilization of signal about 10-15 minutes after sensor placement. Bioimpedance and Doppler pulse waveform analysis were performed by measuring the minimum and maximum distance of pulse waves during 10-second periods. For noise reduction, a 0.1 sec smoothing was used. Data were generated in DataLyser and exported into an Excel (Microsoft, Redmond, WA) spreadsheet for further calculations. Additionally, data from anesthetic monitoring of electrocardiography, pulse oximetry, and capnography were also stored as analog waveforms with a 300 Hz sampling rate. Trends were also recorded for pre and post operative heart rate, noninvasive blood pressure, body temperature, inhaled isoflurane concentration, and bispectral index (BIS) value with 10 sec/number. Since inflammation developed after surgery, an inflammation score was created and compared between groups. Weekly body weights were also recorded and compared between groups. The uninjured left limb was used as the negative control, and data are expressed as the difference between the left (uninjured) and right (injured) sides. ANOVA was used to compare data of four groups (Prism, GraphPad Software Inc., La Jolla, CA). Statistical significance was considered as P< 0.05.

## 3 Results

The average body weight of pigs was  $37.73 \pm 2.34$  kg (mean  $\pm$ SD) at surgery. There was no significant difference among groups.

The left-right side difference was not significantly different among treatment groups in the inflammation severity score, NIRS, Doppler, and BI data. However, some notable trends emerged.

### NIRS

The NIRS trend for the SFT group showed a distinct time course compared to the other three treatments (see Figure 3). The NIRS difference increased between the first postoperative measurement and the 1 week postoperative measurement in SFT, PFT and BF (Copios) groups but not for BC.

### *Blood flow*

The blood flow difference in tibialis anterior arteries was the smallest in PFT group; Figure 4.

### *Bioimpedance*

BI pulse left – right side difference showed a nearly identical time course in all four groups (Figure 5).

A comparison of the three measured modalities shows that while BI and BF differences were minimal in all 4 groups, NIRS laterality difference showed a time-related alteration with maximal difference at one week in the SFT group and at 2 weeks in the other three groups. Furthermore, the PFT group difference increased further from week 2 to week 3 while the others decreased (Figures 6 and 7).

## **4 Discussion**

In this study we used a swine model of femur fracture treated with one of four compounds and analyzed three surrogate markers of wound healing measured by noninvasive monitoring methods. Biochemical markers of bone and wound healing, inflammation, imaging and histology methods and results published elsewhere [17].

Blast exposure causes more complex and multiple forms of damage than any other wounding agent, are the leading cause of death on the battlefield, and are often used by terrorists [18]. During combat operations, extremities continue to be the most common sites of injury. Despite advances in management of combat wounds, wound infection continues to be a troublesome yet potentially preventable complication of combat-related injuries. Inflammation is an essential component of the adult wound response [19]. The challenge for the surgeon is to prevent sepsis while avoiding amputation, which often requires a hard decision for saving extremities [20]. Traumatology problems are described elsewhere [21].

Extremity vascular injuries predominate on the modern battlefield, representing 50 to 70% of all injuries treated during Operation Iraqi Freedom. Furthermore, exsanguination from extremity wounds is the leading cause of preventable death on the modern battlefield. The management of extremity vascular injuries on the modern battlefield presents many unique and demanding challenges to even the most seasoned of surgeons [22].

The treatment of extremity combat wounds is a complex problem that requires a multidisciplinary approach [23]. The common complications associated with lower extremity trauma and amputations secondary to combat injuries were detailed elsewhere [24]. Plasma and cellular biomarkers of injury as predictors of subsequent septic complications have also been detailed [25]. It would have practical importance if wound healing could be evaluated by noninvasive methods that offer quantitative information on bone and soft-tissue healing [26]. The healing of wounds, including bone fractures, involves factors such as revascularization, tissue oxygenation, inflammation, edema formation, which have been detailed elsewhere [27]. Various categories of drugs have been used in the treatment of healing wounds and fractures, including drugs with anti-inflammatory, antipyretic, analgesic, and ossification stimulant effects [28]. However, changes in these modalities during wound healing may influence all three measured modalities.

While the differences among the four measured treatment modalities were statistically non-significant, possible trends in laterality differences are apparent when the data is analyzed graphically as a function of time.

A sham group was unavailable. Consequently, we did not have a control group to compare laterality difference in normal wound healing to that of wound healing with the applied treatments.. Analysis of additional physiologic data is underway and may shed further light on the effects of these treatment and evaluation modalities.

#### 4.1 NIRS

The understanding of the role of oxygen in wound healing has undergone a major evolution from its long-recognized importance as an essential factor for oxidative metabolism to its recognition as an important cell signaling mediator interacting with growth factors and other signals to regulate signal transduction pathways [29]. Accurate measurements of tissue oxygen tension has led to an understanding of the crucial role of oxygen in wound healing and the degree to which oxygen supply in wounded tissue is often the limiting factor in healing [30]. Since transcutaneous oximetry can be used to measure the peri-wound oxygen tension, a consensus statement was established defining tissue hypoxia as oxygen tension <40 mmHg. Healing was considered measuring above this value referring adequate revascularization [31].

NIRS reflects regional tissue oxygenation, with the light-based signal penetrating to a tissue depth of approximately 25 mm in case of the NIRS device used in this study. The measurement provides an estimate of mixed arterial and venous oxygen levels. The lack of significant laterality difference in our study can be interpreted to mean that re-vascularization in the damaged area proceeded similarly in all cases regardless of the treatment. It is also noted that NIRS can be used to quantify total heme oxidation, but it is unable to distinguish between hemoglobin and myoglobin [32]. This fact may also have contributed to our non-significant NIRS results. An overview of the clinical application of NIRS can be found elsewhere [33].

The pig has been suggested as an excellent potential animal model for human wound healing [34]; however, we have noted that inflammation due to infection present during healing may influence measured modalities, as has been shown in other studies [35, 36].

#### 4.2 Blood flow

Extremity vascular injuries on the battlefield require special attention since hemorrhage is the dominant cause of mortality ([8, 22, 37]. Doppler ultrasound is used frequently in clinical practice to diagnose peripheral arterial disease [38]. Modalities for noninvasive monitoring of peripheral perfusion were detailed elsewhere [39]. Blood flow through the femoral artery was deliberately not compromised because the trial was not designed to evaluate healing in the presence of major arterial damage. This may explain the non-significant difference between healthy and affected areas.

#### 4.3 Bioimpedance

The impedance plethysmography method (also called bioimpedance) measures the electrical resistance to an alternating current (i.e., impedance) in a region of the body [40]. In comparison to other tissues, blood is a very good conductor [41]. Therefore, blood volume changes can be recognized by measuring impedance changes. Impedance plethysmography can be taken on almost any body segment.

Measurement typically requires four electrodes to be applied to the body surface. In our study, we used a 2 electrode system with 125 kHz frequency and less than 1 mA amplitude. The current is imperceptible to the patient and does not cause any physiological reaction. The voltage corresponds with the impedance of the body segment and changes with the variation of blood volume variations. On this basis, blood flow can be measured and analyzed [42]. In routine clinical practice mostly used as venous occlusion plethysmography is used for the diagnosis of venous thrombosis and impedance plethysmography measured on the thorax is a special diagnostic application and is usually called impedance cardiography [43, 44]. Bioimpedance measures the conductive ion-containing volume between 2 electrodes. The lack of significant laterality difference suggests that the injury-related edema formation, re-vascularization, and inflammation were similar for all four treatments.

## 5 Conclusion

Hematoma and edema formation, vascularization, infection, bone healing, ion content of treatment and solvent material, as well as its fixation and absorption were potential influencing factors of measured modalities. Because the physiological parameters collected were non-invasive, this process offers the possibility of convenient measurable parameters of wound healing in humans as well. Further studies may incorporate these methods into an injury index, which may provide quantitative assessment of traumatic wound healing over time.

### Funding

This research project was supported by funding from the US Army Military Research and Materiel Command, Ft. Detrick, MD. (W81XWH-09-2-0179) and by The Uniformed Services University of the Health Sciences, Bethesda, MD (grant R0702A)

### Disclaimer

The views of the authors do not purport to reflect the position of the Uniformed Services University or the Department of Defense.

### Acknowledgements


The authors acknowledge the members of the USU Laboratory Animal Medicine department for expert surgical and animal support and members of the Pathology Department, Armed Forces Radiobiology Research Institute for sample processing; L. Baranyi for DataLyser use. B. Jones and K. Brady also provided expert technical assistance.

## REFERENCES


1. Murphy SL, Xu J, Kenneth D. Kochanek KD. Deaths: Preliminary Data for 2010. National Vital Statistics Reports, Volume 60, Number 4 January 11, 2012.  
[http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60\\_04.pdf](http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_04.pdf)
2. Schoenfisch AL, Lipscomb HJ, Shishlov K, Myers DJ. Nonfatal construction industry-related injuries treated in hospital emergency departments in the United States, 1998-2005. Am J Ind Med. 2010 Jun;53(6):570-80.
3. Derlet RW, Silva J Jr, Holcroft J. Pedestrian accidents: adult and pediatric injuries. J Emerg Med. 1989 Jan-Feb;7(1):5-8.
4. Anonymous, 2004. National Foundation For Trauma Care brochure, May 2004 The National Foundation for Trauma Care; <http://www.traumafoundation.org/publications.htm>
5. Peng RY, Bongard FS. Pedestrian versus motor vehicle accidents: an analysis of 5,000 patients. J Am Coll Surg. 1999 Oct;189(4):343-8.
6. Small TJ, Sheedy JM, Grabs AJ. Cost, demographics and injury profile of adult pedestrian trauma in inner Sydney. ANZ J Surg. 2006 Jan-Feb;76(1-2):43-7.
7. Bellamy RF, Maningas PA, Vayer JS. Epidemiology of trauma: military experience. Ann Emerg Med. 1986 Dec;15(12):1384-8.
8. Holcomb JB, McMullin NR, Pearse L, Caruso J, Wade CE, Oetjen-Gerdes L, Champion HR, Lawnick M, Farr W, Rodriguez S, Butler FK. Causes of death in U.S. Special Operations Forces in the global war on terrorism: 2001-2004. Ann Surg. 2007 Jun;245(6):986-91.
9. Fox LC, Kreishman MP. High-energy trauma and damage control in the lower limb. Semin Plast Surg. 2010 Feb;24(1):5-10.
10. Fox CJ, Perkins JG, Kragh JF Jr, Singh NN, Patel B, Ficke JR. Popliteal artery repair in massively transfused military trauma casualties: a pursuit to save life and limb. J Trauma. 2010 Jul;69 Suppl 1:S123-34.
11. Hospenthal DR, Murray CK. Preface: Guidelines for the prevention of infections associated with combat-related injuries: 2011 update. J Trauma. 2011 Aug;71(2 Suppl 2):S197-201.
12. Murray CK. Epidemiology of infections associated with combat-related injuries in Iraq and Afghanistan. J Trauma. 2008 Mar;64(3 Suppl):S232-8.
13. Anonymous: Near infrared spectroscopy. The INVOS® System (Cerebral/Somatic Oximeter (Somanetics, Troy, MI) <http://www.somanetics.com>
14. Anonymous: Plethysmograph - <http://www.freepatentsonline.com/3835840.html>)
15. Bodo M, Garcia A, Pearce F, vanAlbert S, Armonda R. Influence of volume and flow change on the electrical impedance signal (in vitro). 2010 J. Phys.: Conf. Ser. **224** 012111  
doi: [10.1088/1742-6596/224/1/012111](https://doi.org/10.1088/1742-6596/224/1/012111)
16. Majetschak, M., et al., Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma. J Trauma, 2004. **56**(5): p. 991-9; discussion 999-1000.
17. Rothwell SW, Settle TL, Sawyer E, Lombardini E, Royal J, Tang H, Bodo M. Comparison of salmon and porcine fibrinogen and collagen-based treatments for comminuted fractures in a swine femur fracture model.
18. Champion HR, Holcomb JB, Young LA. Injuries from explosions: physics, biophysics, pathology, and required research focus. J Trauma. 2009 May;66(5):1468-77; discussion 1477.
19. Doshi BM, Perdrizet GA, Hightower LE. Wound healing from a cellular stress response perspective. In: Cell stress and chaperones. Volume 13, Number 4, 393-399, 2008, DOI: 10.1007/s12192-008-0059-8
20. Penn-Barwell JG. Outcomes in lower limb amputation following trauma: a systematic review and meta-analysis. Injury. 2011 Dec;42(12):1474-9.
21. LaStayo PC, Winters KM, Hardy M. Fracture healing: bone healing, fracture management, and current concepts related to the hand. J Hand Ther. 2003 Apr-Jun;16(2):81-93.

22. Starnes BW, Beekley AC, Sebesta JA, Andersen CA, Rush RM Jr. Extremity vascular injuries on the battlefield: tips for surgeons deploying to war. *J Trauma*. 2006 Feb;60(2):432-42.
23. Guthrie HC, Clasper JC, Kay AR, Parker PJ; Limb Trauma and Wounds Working Groups, DMST. Initial extremity war wound debridement: a multidisciplinary consensus. *J R Army Med Corps*. 2011 Jun;157(2):170-5.
24. Ursone RL. Unique complications of foot and ankle injuries secondary to warfare. *Foot Ankle Clin*. 2010 Mar;15(1):201-8.
25. Schöffel U, Bonnaire F, van Specht BU, Kuner EH. Monitoring the response to injury. *Injury*. 1991 Sep;22(5):377-82.
26. Covey DC, Aaron RK, Born CT, Calhoun JH, Einhorn TA, Hayda RA, Levin LS, Mazurek MT, Murray CK, Powell ET, Schwarz EM, Wenke JC. Orthopaedic war injuries: from combat casualty care to definitive treatment: a current review of clinical advances, basic science, and research opportunities. *Instr Course Lect*. 2008;57:65-86.
27. Hausman MR, Rinker BD. Intractable wounds and infections: the role of impaired vascularity and advanced surgical methods for treatment. *Am J Surg*. 2004 May;187(5A):44S-55S.
28. Beck A, Salem K, Krischak G, Kinzl L, Bischoff M, Schmelz A. Nonsteroidal anti-inflammatory drugs (NSAIDs) in the perioperative phase in traumatology and orthopedics effects on bone healing. *Oper Orthop Traumatol*. 2005 Dec;17(6):569-78.
29. Tandara AA, Mustoe TA. Oxygen in wound healing-more than a nutrient. *World Journal of Surgery*, Volume 28, Number 3, 294-300, DOI: 10.1007/s00268-003-7400-2.
30. Hopf HW, Hunt TK, Scheuenstuhl H, West JM, Humphrey LM and Rollins MD. Methods of measuring oxygen in wounds. In: *Wound Healing. Methods in Molecular Medicine™*, 2003, Volume 78, II, 389-416, DOI: 10.1385/1-59259-332-1:389
31. Fife CE, Smart DR, Sheffield PJ, Hopf HW, Hawkins G, Clarke D. Transcutaneous oximetry in clinical practice: consensus statements from an expert panel based on evidence. *Undersea Hyperb Med*. 2009 Jan-Feb;36(1):43-53.
32. Spires J, Lai N, Zhou H, Saidel GM. Hemoglobin and myoglobin contributions to skeletal muscle oxygenation in response to exercise. *Adv Exp Med Biol*. 2011;701:347-52.
33. Scheeren TWL, Schober P, Schwarte LA. Monitoring tissue oxygenation by near infrared spectroscopy (NIRS): background and current applications. *Journal of Clinical Monitoring and Computing* Volume 26, Number 4 (2012), 279-287, DOI: 10.1007/s10877-012-9348-y
34. Sullivan TP, Eaglstein WH, Davis SC, Mertz P. The pig as a model for human wound healing. *Wound Repair Regen*. 2001 Mar-Apr;9(2):66-76.
35. Petersen K, Riddle MS, Danko JR, Blazes DL, Hayden R, Tasker SA, Dunne JR. Trauma-related infections in battlefield casualties from Iraq. *Ann Surg*. 2007 May;245(5):803-11.
36. Murray CK, Wilkins K, Molter NC, Li F, Yu L, Spott MA, Eastridge B, Blackbourne LH, Hospenthal DR. Infections complicating the care of combat casualties during operations Iraqi Freedom and Enduring Freedom. *J Trauma*. 2011 Jul;71(1 Suppl):S62-73.
37. Fox CJ, Perkins JG, Kragh JF Jr, Singh NN, Patel B, Ficke JR. Popliteal artery repair in massively transfused military trauma casualties: a pursuit to save life and limb. *J Trauma*. 2010 Jul;69 Suppl 1:S123-34.
38. Pellerito JS. Current approach to peripheral arterial sonography. *Radiol. Clin. North Am*. 2001 May;39(3):553-67.
39. Lima A, Bakker J. Noninvasive monitoring of peripheral perfusion. *Intensive Care Med*. 2005 Oct;31(10):1316-26. Epub 2005 Sep 17.
40. Nyboer J. Regional pulse volume and perfusion flow measurement. *AMA Arch Internat Med* 1960;105: 264-76.


41. Nyboer J. Electro-rheometric properties of tissues and fluids. Ann. New York Acad.Sci.1970; 170:410-420.
42. Anonymous. Medis GmbH web site. Impedance Plethysmography  
[http://www.medis-de.com/index.php?option=com\\_content&task=view&id=37&Itemid=62](http://www.medis-de.com/index.php?option=com_content&task=view&id=37&Itemid=62)
43. Kubicek WG. Minnesota Impedance Cardiograph. Crit Care Med. 1995 Oct;23(10):1785-6.
44. Bernstein DP. Impedance cardiography: Pulsatile blood flow and the biophysical and electrodynamic basis for the stroke volume equations. Journal of Electrical Bioimpedance, vol 1, 2010 pp 2-17  
<https://www.journals.uio.no/index.php/bioimpedance/article/view/51>




**Fig 1. Sensor and electrode placement**




**Fig. 2. Left – right differences of NIRS values as a function of time in four treatment groups. .**



**Fig. 3.** Left – right differences of impedance pulse values as a function of time.



**Fig.4.** Left – right differences of blood flow values as a function of time



**Fig 6. Left – right differences of NIRS, blood flow, and impedance values as a function of time by treatment groups. Legend: before: pre-surgery; after: post-surgery; 1w: one week after surgery; 2w: two weeks after surgery; 3w: three weeks after surgery.**